Arcadia Biosciences (RKDA) 10-K 30 Mar 23 2022 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2022	Mar. 23, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Registrant Name	Arcadia Biosciences, Inc.
Entity Central Index Key	0001469443
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding		857,572
Entity Public Float			$ 21,027,600
Stock price			$ 40
Entity Listing, Par Value Per Share	$ 0.001
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Small Business	true
Entity File Number	001-37383
Entity Tax Identification Number	81-0571538
Entity Address, Address Line One	5950 Sherry Lane
Entity Address, Address Line Two	Suite 215
Entity Address, City or Town	Dallas
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75225
City Area Code	214
Local Phone Number	974-8921
Entity Incorporation, State or Country Code	DE
Trading Symbol	RKDA
Title of 12(b) Security	Common
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Annual Report	true
Document Transition Report	false
ICFR Auditor Attestation Flag	false
Documents Incorporated by Reference	Information required by Part III of this Annual Report on Form 10-K is incorporated by reference to the Registrant's Definitive Proxy Statement for its 2022 Annual Meeting of Stockholders, which proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year covered by this Form 10-K.
Auditor Firm ID	34
Auditor Name	Deloitte & Touche LLP
Auditor Location	Tempe, AZ

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 20,644	$ 28,685
Accounts receivable and other receivables, net of allowance for doubtful accounts of $3 and $76 as of December 31, 2022 and 2021, respectively	1,287	1,370
Inventories, net — current	2,571	4,433
Assets held for sale	87	0
Prepaid expenses and other current assets	809	900
Total current assets	25,398	35,388
Property and equipment, net	704	2,291
Right of use assets	1,848	3,081
Inventories, net — noncurrent	767	2,494
Intangible assets, net	40	484
Other noncurrent assets	165	180
Total assets	28,922	43,918
Current liabilities:
Accounts payable and accrued expenses	2,881	3,638
Amounts due to related parties	48	64
Operating lease liability - current	1,010	1,074
Other current liabilities	270	264
Total current liabilities	4,209	5,040
Operating lease liability - noncurrent	1,007	2,220
Common stock warrant and option liabilities	806	3,392
Other noncurrent liabilities	2,000	2,070
Total liabilities	8,022	12,722
Commitments and contingencies (Note 16)
Stockholders’ equity:
Common stock, $0.001 par value-150,000,000 shares authorized as of December 31, 2022 and December 31, 2021; 616,079 and 554,609 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively.	65	63
Additional paid-in capital	278,827	257,515
Accumulated deficit	(257,859)	(226,485)
Total Arcadia Biosciences stockholders’ equity	21,033	31,093
Non-controlling interest	(133)	103
Total stockholders' equity	20,900	31,196
Total liabilities and stockholders’ equity	$ 28,922	$ 43,918

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 3,000	$ 76,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	150,000,000	150,000,000
Common stock, issued	616,079	554,609
Common stock, outstanding	616,079	554,609

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total revenues	$ 9,956,000	$ 6,780,000
Operating expenses (income):
Cost of revenues	9,802,000	8,708,000
Research and development	1,509,000	3,889,000
(Gain) on sale of Verdeca	(1,138,000)	0
Loss on sale of Arcadia Spain	0	497,000
Impairment of intangible assets	404,000	3,302,000
Impairment of goodwill	0	1,648,000
Change in fair value of contingent consideration	(70,000)	(210,000)
(Gain) on sale of property and equipment	(314,000)	23,000
Impairment of property and equipment, net	530,000	1,534,000
Selling, general and administrative	18,048,000	22,938,000
Total operating expenses	28,771,000	42,306,000
Loss from operations	(18,815,000)	(35,526,000)
Interest income (expense)	289,000	(20,000)
Other income, net	33,000	10,114,000
Change in fair value of common stock warrant and option liabilities	3,209,000	8,946,000
Gain on extinguishment of PPP loan	0	1,123,000
Issuance and offering costs	(314,000)	(769,000)
Net loss before income taxes	(15,598,000)	(16,132,000)
Income tax (provision)	(14,000)	(2,000)
Net loss	(15,612,000)	(16,134,000)
Net loss attributable to non-controlling interest	(236,000)	(1,474,000)
Net loss attributable to common stockholders	$ (15,376,000)	$ (14,660,000)
Net loss per share attributable to common stockholders:
Basic net loss per share attributable to common stockholders:	$ (25.65)	$ (27.56)
Diluted net loss per share attributable to common stockholders:	$ (25.65)	$ (27.56)
Weighted-average number of shares used in per share calculations:
Weighted average shares - Basic	599,389	532,016
Weighted average shares - Diluted	599,389	532,016
Other comprehensive loss	$ 0	$ 0
Comprehensive loss attributable to common stockholders	(15,376,000)	(14,660,000)
Product
Revenues:
Total revenues	8,960,000	6,587,000
License
Revenues:
Total revenues	879,000	17,000
Royalty
Revenues:
Total revenues	$ 117,000	$ 176,000

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Arcadia Wellness [Member]	August 2022 Offering [Member]	January 2021 PIPE [Member]	Common Stock [Member]	Common Stock [Member] Arcadia Wellness [Member]	Common Stock [Member] August 2022 Offering [Member]	Common Stock [Member] January 2021 PIPE [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member] Arcadia Wellness [Member]	Additional Paid-In Capital [Member] August 2022 Offering [Member]	Additional Paid-In Capital [Member] January 2021 PIPE [Member]	Accumulated Deficit [Member]	Non-Controlling Interest [Member]
Stockholders Equity, Beginning Balance at Dec. 31, 2020	$ 28,552				$ 54				$ 239,496				$ (211,825)	$ 827
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2020					336,272
Issuance of shares				$ 15,516				$ 8				$ 15,508
Issuance of shares, Shares								196,920
Offering costs				(2,084)								(2,084)
Issuance of placement agent warrants				$ 942								$ 942
Issuance of common stock at closing of acquisition transaction		$ 2,053				$ 1				$ 2,052
Issuance of common stock at closing of acquisition transaction, Shares						20,686
Issuance of shares related to exercise of Service and Performance Warrants	22								22
Issuance of shares related to exercise of Service and Performance Warrants, Shares					350
Issuance of shares related to employee stock purchase plan	38								38
Issuance of shares related to employee stock purchase plan, Shares					381
Stock-based compensation	1,541								1,541
Non-controlling interest contributions	750													750
Net loss	(16,134)												(14,660)	(1,474)
Stockholders Equity, Ending Balance at Dec. 31, 2021	31,196				$ 63				257,515				(226,485)	103
Stockholders Equity, Ending Balance (Accounting Standards Update 2020-06 Retrospective [Member]) at Dec. 31, 2021	$ 3,392								19,390				(15,998)
Stockholders Equity, Ending Balance, Shares at Dec. 31, 2021					554,609
Accounting Standards Update [Extensible Enumeration]	Accounting Standards Update 2020-06 [Member]
Issuance of shares			$ 1,176				$ 2				$ 1,174
Issuance of shares, Shares							61,250
Offering costs			$ (365)								$ (365)
Issuance of shares related to employee stock purchase plan	$ 7								7
Issuance of shares related to employee stock purchase plan, Shares					220
Stock-based compensation	1,106								1,106
Net loss	(15,612)												(15,376)	(236)
Stockholders Equity, Ending Balance at Dec. 31, 2022	$ 20,900				$ 65				$ 278,827				$ (257,859)	$ (133)
Stockholders Equity, Ending Balance, Shares at Dec. 31, 2022					616,079

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (15,612,000)	$ (16,134,000)
Adjustments to reconcile net loss to cash used in operating activities:
Change in fair value of common stock warrant and option liabilities	(3,209,000)	(8,946,000)
Change in fair value of contingent consideration	(70,000)	(210,000)
Issuance and offering costs	314,000	769,000
Depreciation	439,000	929,000
Amortization of intangible assets	40,000	116,000
Lease amortization	884,000	1,276,000
Impairment of intangible assets	404,000	3,302,000
Impairment of goodwill	0	1,648,000
(Gain) Loss on disposal of equipment	(314,000)	23,000
Loss on disposal of intangible assets	0	222,000
Stock-based compensation	1,106,000	1,541,000
Bad debt expense	60,000	76,000
Gain on sale of Verdeca	(1,138,000)	0
Realized gain on corporate securities	0	(10,221,000)
Write-down of inventories	2,471,000	3,593,000
Gain on extinguishment of PPP loan	0	(1,123,000)
Impairment of property and equipment	530,000	1,534,000
Changes in operating assets and liabilities:
Accounts receivable and other receivables	592,000	(40,000)
Inventories	1,118,000	(2,383,000)
Prepaid expenses and other current assets	91,000	56,000
Other noncurrent assets	16,000	(158,000)
Accounts payable and accrued expenses	(757,000)	(372,000)
Amounts due to related parties	(16,000)	(16,000)
Unearned revenue	0	(8,000)
Other current liabilities	6,000	1,000
Operating lease payments	(932,000)	(1,343,000)
Net cash used in operating activities	(13,977,000)	(25,868,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of property and equipment	920,000	19,000
Proceeds from sale of Verdeca - earn-out received	569,000
Purchases of property and equipment	(72,000)	(1,007,000)
Acquisitions, net of cash acquired	0	(4,250,000)
Proceeds from sales and maturities of investments	0	21,846,000
Net cash provided by investing activities	1,417,000	16,608,000
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments on notes payable	0	(2,146,000)
Proceeds from exercise of warrants	0	22,000
Proceeds from exercise of stock options and purchases through ESPP	7,000	39,000
Capital contributions received from non-controlling interest	0	750,000
Net cash provided by financing activities	4,519,000	21,900,000
Effects of foreign currency translation on cash and cash equivalents	0	2,000
Net increase (decrease) in cash, cash equivalents and restricted cash	(8,041,000)	12,642,000
Cash, cash equivalents and restricted cash — beginning of period	28,685,000	16,043,000
Cash, cash equivalents and restricted cash — end of period	20,644,000	28,685,000
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	1,000	25,000
Cash paid for taxes	0	1,000
NONCASH TRANSACTIONS:
Fair value of shares of common stock issued at closing of Arcadia Wellness transaction	0	2,053,000
Right of use assets obtained in exchange for new operating lease liabilities	114,000	1,664,000
Proceeds From Sale Of Property And Equipment In Accounts Receivable And Other Receivables	19,000	0
Proceeds from sale of Verdeca in accounts receivable and other receivables	569,000	0
Accounting Standards Update 2020-06 [Member]
NONCASH TRANSACTIONS:
Common stock warrant liabilities reclassified to equity	3,392,000	0
August 2022 Offering [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, pre-funded warrants and preferred investment options	5,000,000	0
Payments of offering costs	(488,000)	0
January 2021 PIPE Purchase Agreement [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants from offering	0	25,147,000
Payments of offering costs	0	(1,912,000)
NONCASH TRANSACTIONS:
Common stock warrants issued to placement agent and included in offering costs related to purchase agreement	0	942,000
August 2022 RDO Securities Purchase Agreement [Member]
NONCASH TRANSACTIONS:
Common stock options issued to placement agent and included in offering costs	$ 191,000	$ 0

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Description of Business	Note 1. Description of Business Organization Arcadia Biosciences, Inc. (the "Company," "Arcadia" or "management"), was incorporated in Arizona in 2002 and maintains its headquarters in Dallas, Texas, with additional office space in Davis, California, and additional facilities in American Falls, Idaho. The Company was reincorporated in Delaware in March 2015 . The Company is a producer and marketer of innovative, plant-based food and beverage products. Its history as a leader in science-based approaches to developing high-value crop improvements, as well as nutritionally enhanced food ingredients, has laid the foundation for its path forward. The Company used advanced breeding techniques to develop these proprietary innovations which are now being commercialized through the sales of seed and grain, as well as food ingredients and products. The acquisition of the assets of Live Zola, LLC (“Zola”) added coconut water to the Company's portfolio of products. In May 2021, the Company’s wholly owned subsidiary Arcadia Wellness, LLC (“Arcadia Wellness” or “AW”, see Note 7), acquired the businesses of Eko, Lief, and Zola. The acquisition included consumer CBD brands like Soul Spring™, a CBD-infused botanical therapy brand in the natural category, Saavy Naturals™, a line of natural body care products and ProVault™, a CBD-infused sports performance formula made with natural ingredients, providing effective support and recovery for athletes. Also included in the purchase was Zola, a coconut water sourced exclusively with sustainably grown coconuts from Thailand. On July 8, 2022, the Company entered into an agreement to license Saavy Naturals™ to Radiance Beauty and Wellness, Inc. ("Radiance Beauty"). See Note 7 for a discussion of the licensing agreement. In April 2021, the newly formed Company’s wholly owned subsidiary Arcadia SPA, S.L. (“Arcadia Spain” or “ASPA”) acquired the physical and intellectual property assets of Agrasys S.A. (“Agrasys”), a food ingredients company based in Barcelona, Spain. The Company sold all of the assets and liabilities related to the subsidiary Arcadia Spain in November 2021 to a European buyer (the "buyer"), to focus on the US domestic market. The loss on sale of Arcadia Spain recorded on the consolidated statements of operations and comprehensive loss was $ 497,000 . The buyer assumed all present and future liabilities, including the initial commitments related to the 2022 planting season. In August 2019, the Company entered into a joint venture agreement with Legacy Ventures Hawaii, LLC (“Legacy,” see Note 9) to grow, extract, and sell hemp products. The partnership Archipelago Ventures Hawaii, LLC (“Archipelago”), combines the Company’s extensive genetic expertise and resources with Legacy’s experience in hemp extraction and sales. In October 2021, Arcadia and Legacy mutually agreed to wind down the cultivation activities of Archipelago, due to regulatory challenges and a saturated hemp market. As a result, the Company recorded impairments of property and equipment in the amount of $ 160,000 and $ 1.4 million for the years ended December 31, 2022, and 2021, respectively. The Company assessed Archipelago’s fixed assets for impairment through an asset recoverability test, using prices for similar assets. See Note 5. Reverse Stock Split In February 2023, the Company’s board of directors approved a reverse split of 40:1 on the Company’s issued and outstanding common stock. On February 15, 2023, the Company’s stockholders approved the certificate of amendment, which the Company filed on February 27, 2023 with the Secretary of State of Delaware to effect the reverse split on March 1, 2023. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the consolidated financial statement have been retroactively adjusted to reflect the reverse stock split for all periods presented . Liquidity, Capital Resources, and Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. Since inception, the Company has financed its operations primarily through equity and debt financings. As of December 31, 2022, the Company had an accumulated deficit of $ 257.9 million, and cash and cash equivalents of $ 20.6 million. For the years ended December 31, 2022 and 2021, the Company had net losses of $ 15.6 million and $ 16.1 million, respectively, and net cash used in operations of $ 14.0 million and $ 25.9 million, respectively. The Company believes that its existing cash and cash equivalents will not be sufficient to meet its anticipated cash requirements for at least the next 12-18 months from the issuance date of these financial statements, and thus raises substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company may seek to raise additional funds through debt or equity financings. The Company may also consider entering into additional partner arrangements. The sale of additional equity would result in dilution to the Company’s stockholders. The incurrence of debt would result in debt service obligations, and the instruments governing such debt could provide for additional operating and financing covenants that would restrict operations. If the Company does require additional funds and is unable to secure adequate additional funding at terms agreeable to the Company, the Company may be forced to reduce spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned development programs. Any of these actions could materially harm the business, results of operations and financial condition.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The consolidated financial statements include the accounts of the Company, Arcadia Wellness and Archipelago. All intercompany balances and transactions have been eliminated in consolidation. The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP (“GAAP”), and with the rules of the Securities and Exchange Commission. The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities ("VIEs"). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIE’s economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE. For all periods presented, the Company has determined that it is the primary beneficiary of Archipelago, a joint venture, as it has a controlling interest in Archipelago. Accordingly, the Company consolidates Archipelago in the consolidated financial statements after eliminating intercompany transactions. For consolidated joint ventures, the non-controlling partner’s share of the assets, liabilities and operations of the joint venture is included in non-controlling interests as equity of the Company. The non-controlling partner’s interest is generally computed as the joint venture partner’s ownership percentage of Archipelago. Net loss attributable to non-controlling interest of $ 236,000 and $ 1.5 million is recorded as an adjustment to net loss to arrive at net loss attributable to common stockholders for the years ended December 31, 2022 and 2021, respectively. The non-controlling partner’s equity interests are presented as non-controlling interests on the consolidated balance sheets as of December 31, 2022 and 2021. The functional currency of the foreign subsidiary Arcadia Spain during the year ended December 31, 2021, was its local currency (i.e., the Euro). Accordingly, period-end exchange rates were applied to translate its assets and liabilities and average transaction exchange rates to translate its revenues, expenses, gains, and losses into U.S. dollars. Upon disposal of all of the assets and liabilities related to Arcadia Spain, the Company deconsolidated the accounts of the subsidiary as of November 30, 2021, and recorded a loss on the sale in the amount of $ 497,000 during the year ended December 31, 2021. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions in the Company’s consolidated financial statements and notes thereto. Significant estimates and assumptions made by management included the determination of the provision for income taxes, stock-based compensation, impairments of long-lived assets such as intangible assets and goodwill, impairment of property and equipment, net realizable value of inventory, and contingent liabilities. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Cash and cash equivalents The Company considers any liquid investment with a stated maturity of three months or less at the date of purchase to be a cash equivalent. Cash and cash equivalents consist of cash on deposit with banks and money-market funds. The Company limits cash investments to financial institutions with high credit standings; therefore, management believes that there is no significant exposure to any credit risk in the Company’s cash and cash equivalents. However, as of December 31, 2022 and 2021, a portion of the Company’s cash in depository accounts is in excess of the federal deposit insurance limits. Investments in debt and equity securities Investments in debt and equity securities are carried at fair value and classified as short-term investments. Realized and unrealized gains and losses on investment securities are included in other income, net, in the consolidated statements of operations and comprehensive loss. Investment securities are reported as cash and cash equivalent, short-term investments or long-term investments in the consolidated balance sheets based on the nature of the investments and maturity period. Short-term investments have maturities of less than a year and long-term investments have maturities of a year and greater from the balance sheet date. Other-than-temporary impairments on investments The Company regularly reviews each of its investments for impairment by determining if the investment has sustained an other-than-temporary decline in its value, in which case the investment is written down to its fair value by a charge to earnings. Factors that are considered by the Company in determining whether an other-than-temporary decline in value has occurred include (i) the market value of the investment in relation to its cost basis, (ii) the financial condition of the investment, and (iii) the Company’s intent and ability to retain the investment for a sufficient period of time to allow for recovery of the market value of the investment. As of December 31, 2022 and 2021, there was no impairment of the Company’s investments. Accounts receivable and other receivables Accounts receivable represents amounts owed to the Company from product sales, licenses, and royalties. Other receivables represent amounts owed to the Company for miscellaneous non-trade activities including the sale of property and equipment. The carrying value of the Company’s receivables represents estimated net realizable values. The Company generally does not require collateral and estimates any required allowance for doubtful accounts based on historical collection trends, the age of outstanding receivables, and existing economic conditions. If events or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectability of those balances and the allowance is recorded accordingly. Past-due receivable balances are written off when the Company’s internal collection efforts have been unsuccessful in collecting the amounts due. The Company had $ 3,000 and $ 76,000 amounts reserved for doubtful accounts at December 31, 2022 and 2021, respectively, and the allowance activity during the year ended December 31, 2022, was immaterial. Inventory Inventory costs are tracked on a lot-identified basis and are included as cost of revenues when sold. Inventories are stated at the lower of cost or net realizable value. The Company makes adjustments to inventory when conditions indicate that the net realizable value may be less than cost due to physical deterioration, obsolescence, changes in price levels, or other factors. Additional adjustments to inventory are made for excess and slow-moving inventory on hand that is not expected to be sold within a reasonable timeframe to reduce the carrying amount to its estimated net realizable value . GoodWheat: Proprietary wheat plants are grown, producing seed and grain with a variety of improved nutritional qualities, including high levels of amylose, improved shelf life, and reduced gluten. The seed is used for subsequent plantings and the grain is either sold or used as an ingredient in the production of food products, which the Company refers to collectively as GoodWheat products. Amounts inventoried consist primarily of fees paid to contracted cooperators to grow the crops, costs to process harvested seed and grain, and costs to mill the grain into flour. Body care : A portfolio of CBD-infused and CBD-free consumer bath and body care products such as body lotions, bath-bombs and topical pain relievers, that are produced in the US. Amounts inventoried consist primarily of purchased raw materials, components, labor, and manufacturing facility costs. Zola Coconut water : Inventories mainly consist of coconut water imported from Thailand, freight-in, supplies, and labor. GoodHemp : Proprietary seeds are grown and used for subsequent plantings and sold as final product to other growers. Amounts in inventory for internally produced hemp seeds consist primarily of labor, supplies and facility costs. The costs to procure seeds from external growers and suppliers are included in inventory, as well. In addition, hemp seeds were planted on land leased in Hawaii. The costs of purchasing, planting and growing the seed, and harvesting the resulting biomass are captured as inventory, along with the costs to process the biomass into CBD oil. Amounts in inventory for growing biomass primarily consist of labor, supplies and facility costs. The inventories—current line item on the balance sheet represents inventory forecasted to be sold or used in production in the next 12 months, as of the balance sheet date, and consists primarily of the cost of GoodWheat grain, Zola Coconut water, and GoodHemp seeds. The inventories—noncurrent line item on the balance sheet represents inventory expected to be used in production or sold beyond the next 12 months, as of the balance sheet date, and consists primarily of GoodWheat seed and grain. Raw materials inventories consist primarily of GoodWheat seeds and in-transit Zola Coconut Water. Finished goods inventories consist primarily of GoodWheat grain, Zola Coconut Water, and GoodHemp seeds that are available for sale. Property and equipment Property and equipment acquisitions are recorded at cost. Provisions for depreciation are calculated using the straight-line method over the following average estimated useful lives of the assets: Years Laboratory equipment 5 Software and computer equipment 3 Machinery and equipment 2 - 20 Furniture and fixtures 7 Vehicles 5 Leasehold improvements 2 - 10 * *Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the remaining life of the lease. The Company evaluates if events and circumstances have occurred that indicate the remaining estimated useful life of fixed assets may warrant revision or that the remaining balance of these assets may not be recoverable. In evaluating for recoverability, the Company estimates the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. In the event that the balance of any asset exceeds the future undiscounted cash flow estimate, impairment is recognized based on the excess of the carrying amounts of the asset above its estimated fair value. Impairment of long-lived intangible assets and goodwill The Company evaluates if events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and identifiable intangible assets may warrant revision or that the remaining balance of these assets may not be recoverable. In evaluating for recoverability, the Company estimates the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. In the event that the balance of any asset exceeds the future undiscounted cash flow estimate, impairment is recognized based on the excess of the carrying amounts of the asset above its estimated fair value. Intangible assets, net During the years ended December 31, 2022 and 2021, there were $ 404,000 and $ 3.3 million, respectively of impairm ent of intangible assets, recorded on the consolidated statements of operations and comprehensive loss. See Note 8 for more information. Goodwill No goodwill impairment charges were recorded during the year ended December 31, 2022. During the year ended December 31, 2021, the Company recorded an impairment charge of $ 1.6 million, which was included as impairment of goodwill on our consolidated statements of operations and comprehensive loss. The impairment charge was primarily the result of weakness in our newly acquired consumer product margins combined with a volatile economic climate and higher than normal inflation. The decline in the stock price observed during the fourth quarter of 2021, pushed our market capitalization significantly below the recorded value of our stockholders' equity. Fair value of financial instruments Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. Assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities, are as follows: • Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date. • Level 2 inputs are observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 inputs are unobservable inputs for the asset or liability. The carrying values of the Company’s financial instruments, including cash equivalents, accounts receivable, and accounts payable approximated their fair values due to the short period of time to maturity or repayment. Concentration of risk Cash and cash equivalents are maintained with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate its credit risks by spreading such risks across multiple counterparties and monitoring the risk profiles of these counterparties. Customer concentration Significant customers are those that represent greater than 10% of the Company’s total revenues or gross accounts receivable balance at each respective balance sheet date. Customers representing greater than 10% of accounts receivable were as follows (in percentages): As of 2022 2021 Customer B — 11 Customer D — 15 Customer E — 11 Customer A 57 — Customers representing greater than 10% of total revenues were as follows (in percentages): For Year Ended 2022 2021 Customer D — 11 Customer B — 10 Customer F 13 — Stock-based compensation The Company recognizes compensation expense related to its employee stock purchase plan and the cost of stock-based compensation awards on a straight-line basis over the requisite service period, net of estimated forfeitures. Judgment is required in estimating the amount of stock-based awards that will be forfeited prior to vesting. Compensation expense could be revised in subsequent periods if actual forfeitures differ from those estimates. The Company has selected the Black-Scholes option-pricing model and various inputs to estimate the fair value of its stock-based awards. See Note 15 for additional information. Amounts recognized in the consolidated statements of operations and comprehensive loss were as follows (in thousands): Year Ended December 31, 2022 2021 Research and development $ 75 $ 98 Selling, general and administrative 1,031 1,443 Total stock-based compensation $ 1,106 $ 1,541 Income taxes The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Net loss per share Basic net loss per share, which excludes dilution, is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock, such as stock options, convertible promissory notes, convertible preferred stock, redeemable convertible preferred stock and warrants, result in the issuance of common stock which share in the losses of the Company. Certain potential shares of common stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. Such potentially dilutive shares are excluded when the effect would be to reduce the loss per share. Due to net losses, there is no impact on earnings per share calculation in applying the two-class method since the participating securities have no legal requirement to share in any losses. Revenue recognition The Company derives its revenues from product sales, licensing agreements and royalty fees. Product revenues Product revenues consist primarily of sales of Arcadia Wellness products, GoodWheat grain and pasta, and GLA products. We recognize revenue from product sales when control of the product is transferred to third-party distributors and manufacturers, collectively “our customers,” which generally occurs upon delivery. The Company's revenues fluctuate depending on the timing of shipments of product to our customers and are reported net of estimated chargebacks, returns and losses. License revenues License revenues to date consist of up-front, nonrefundable license fees, annual license fees, and subsequent milestone payments that the Company receives under the Company’s research and license agreements. The Company recognizes revenue generated from up-front, nonrefundable license fees upon execution of the agreement and recognizes annual license fees when it is probable that a material reversal will not occur. Milestone fees are variable consideration that is initially constrained and recognized only when it is probable that such amounts would not be reversed. The Company assesses when achievement of milestones is probable to determine the timing of revenue recognition for milestone fees. Milestones typically consist of significant stages of development for the Company’s traits in a potential commercial product, such as achievement of specific technological targets, completion of field trials, filing with regulatory agencies, completion of the regulatory process, and commercial launch of a product containing the Company’s traits. Given the seasonality of agriculture and time required to progress from one milestone to the next, achievement of milestones is inherently uneven, and the Company’s license revenues are likely to fluctuate significantly from period to period. Royalty revenues Royalty revenues consist of amounts earned from the sale of commercial products that incorporate the Company's traits by third parties. Royalty revenues consist of a minimum annual royalty, offset by amounts earned from the sale of products. The Company recognizes the minimum annual royalty on a straight-line basis over the year, and the Company recognizes royalty revenue resulting from the sale of products when the third parties transfer control of the product to their customers, which generally occurs upon shipment. Royalty revenues can fluctuate depending on the timing of shipments of product by the third parties to their customers. Unearned revenue The Company defers revenue to the extent that cash received in conjunction with a license agreement is not yet earned in accordance with the Company policies. Cost of revenues Cost of revenues relates to the sale of Arcadia Wellness, GoodWheat, and GLA products and consists of the cost of raw materials, including internal and third-party services costs related to procuring, processing, formulating, packaging and shipping our products, as well as in-licensing and royalty fees, any adjustments or write-downs to inventory or prepaid production costs. Research and development expenses Research and development expenses consist of costs incurred in the development and testing of the Company's products and other products in development incorporating the Company's traits. These expenses currently consist primarily of fees paid to product formulation consultants and are expensed as incurred. Additionally, the Company is required from time to time to make certain milestone payments in connection with the development of technologies in-licensed from third parties. The Company's research and development expenses may fluctuate from period to period. Change in fair value of contingent consideration Change in the fair value of contingent consideration is comprised of the gain associated with the reduction of the contingent liability. See Note 6 and Note 16. Change in the estimated fair value of common stock warrant and option liabilities Change in the estimated fair value of common stock warrant and option liabilities is comprised of the fair value remeasurement of liability classified common stock warrants and options. See Note 14.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	12 Months Ended
	Dec. 31, 2022
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	Note 3. Recent Accounting Pronouncements In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. Additionally, the FASB issued ASU No. 2019-04, Codification Improvements to Topic 326 in April 2019 and ASU 2019-05, Financial Instruments — Credit Losses (Topic 326) — Targeted Transition Relief in May 2019. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. In November 2019, the FASB issued ASU No. 2019-10, which defers the effective date of ASU No. 2016-13 for smaller reporting companies to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company adopted A SU No. 2016-13 on January 1, 2023 with an immaterial impact on the Company’s disclosures. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40). The FASB Board is issuing this Update to address issues identified as a result of the complexity associated with applying GAAP for certain financial instruments with characteristics of liabilities and equity. In addressing the complexity, the FASB Board focused on amending the guidance on convertible instruments and the guidance on the derivatives scope exception for contracts in an entity’s own equity. ASU 2020-06 is effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The amendments in this Update are effective for public business entities that meet the definition of a smaller reporting company, as defined by the SEC, for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The Company early adopted ASU No. 2020-06 on January 1, 2022 , using the modified retrospective method. Prior to the adoption of ASU No. 2020-06, the Company had liability classified awards due to the existence of certain contingent cash payment feature. Upon adoption, these clauses no longer preclude equity classification. Under the modified retrospective method, the historical mark-to-market adjustments related to outstanding awards were reversed through retained earnings and the original carrying value of the awards were reclassified to additional paid-in capital. Adoption of the new standard resulted in an increase to accumulated deficit of $ 16.0 million, an increase to additional paid-in capital of $ 19.4 million, and a decrease to common stock warrant liabilities of $ 3.4 million, on the consolidated balance sheets. In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40): Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in this Update clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this Update affect all entities that issue freestanding written call options that are classified in equity. The amendments in this Update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company adopted ASU No. 2021-04 on January 1, 2022 with an immaterial impact on the Company’s disclosures.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventory	Note 4. Inventory Inventory costs are tracked on a lot-identified basis and are included as cost of revenues when sold. Inventories are stated at the lower of cost or net realizable value. The Company makes adjustments to inventory when conditions indicate that the net realizable value may be less than cost due to physical deterioration, obsolescence, changes in price levels, or other factors. Additional adjustments to inventory are made for excess and slow-moving inventory on hand that is not expected to be sold within a reasonable timeframe to reduce the carrying amount to its estimated net realizable value. The write-downs to inventory are included in cost of revenues and are based upon estimates about future demand from the Company’s customers and distributors and market conditions. The Company recorded write-downs of wheat, hemp seed and CBD oil inventories, as well as body care products of $ 2.5 million for the year ended December 31, 2022. Of inventory write-downs during the year ended December 31, 2022, $ 394,000 was related to the Radiance Beauty licensing agreement discussed in Note 7. The Company recorded write-downs of wheat inventories, hemp seed inventories, and body care products of $ 3.6 million for the year ended December 31, 2021. If there are significant changes in demand and market conditions, substantial future write-downs of inventory may be required, which would materially increase the Company’s expenses in the period the write down is taken and materially affect the Company’s operating results. Inventories, net consist of the following (in thousands): December 31, December 31, Raw materials $ 610 $ 1,851 Goods in process — 842 Finished goods 2,728 4,234 Inventories $ 3,338 $ 6,927

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Note 5. Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): As of December 31, 2022 2021 Laboratory equipment $ 679 $ 2,659 Software and computer equipment 407 548 Machinery and equipment 450 1,809 Furniture and fixtures 83 211 Vehicles 306 417 Leasehold improvements 1,590 2,306 Property and equipment, gross 3,515 7,950 Less accumulated depreciation and amortization ( 2,811 ) ( 5,659 ) Property and equipment, net $ 704 $ 2,291 Depreciation expense was $ 439,000 and $ 929,000 for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022 and 2021, there was $ 10,000 and $ 267,000 of construction in progress, respectively, included in property and equipment that had not been placed into service and was not subject to depreciation. Property and equipment are considered assets held for sale when management approves and commits to a plan to dispose of a property or group of properties. The property and equipment held for sale prior to the sale date is separately presented, within current assets, on the consolidated balance sheet as assets held for sale. During the year ended December 31, 2022, management initiated the sale of property and equipment related to the Davis laboratory, Archipelago and Body Care. The Company completed the sale of such property and equipment with a net gain on sale of property and equipment in the amount of $ 314,000 recorded on the consolidated statements of operations and comprehensive loss during the year ended December 31, 2022. The proceeds related to the sale of property and equipment during the year ended December 31, 2022 were $ 920,000 . The Company had no sales of assets held for sale as of December 31, 2021. Property and equipment related to Archipelago, in the amount of $ 87,000 , have been classified as assets held for sale, and are recorded at fair value as of December 31, 2022. During the year ended December 31, 2022, the Company recorded write-downs of property and equipment of $ 530,000 , of which $ 320,000 was related to the Radiance Beauty licensing agreement. See Note 7 for further discussion of the licensing agreement. The Company recorded impairments of property and equipment in the amount o f $ 1.5 million for the year ended December 31, 2021 primarily related to the unwinding of Archipelago. The Company assessed Archipelago’s fixed assets for impairment through an asset recoverability test, calculating the fair value using prices for similar assets.

Investments and Fair Value Inst

Investments and Fair Value Instruments	12 Months Ended
	Dec. 31, 2022
Investments And Fair Value Instruments [Abstract]
Investments and Fair Value Instruments	Note 6. Investments and Fair Value Instruments Investments The investments are carried at fair value, based on quoted market prices or other readily available market information. Unrealized and realized gains and losses are recognized as other income in the consolidated statements of operations and comprehensive loss. During the year ended December 31, 2021, the Company recorded realized gains of $ 10.2 million associated with the sale of corporate securities in other income, net, in the consolidated statements of operations and comprehensive loss. The following tables summarize the amortized cost and fair value of the investment securities portfolio at December 31, 2022 and 2021: (Dollars in thousands) Amortized Unrealized Unrealized Estimated December 31, 2022 Cash equivalents: Money market funds $ 18,620 $ — $ — $ 18,620 Total Assets at Fair Value $ 18,620 $ — $ — $ 18,620 (Dollars in thousands) Amortized Unrealized Unrealized Estimated December 31, 2021 Cash equivalents: Money market funds $ 26,842 $ — $ — $ 26,842 Total Assets at Fair Value $ 26,842 $ — $ — $ 26,842 The Company did no t have any investment categories that were in a continuous unrealized loss position for more than twelve months as of December 31, 2022. Fair Value Measurement The fair value of the investment securities at December 31, 2022 were as follows: Fair Value Measurements at December 31, 2022 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 18,620 $ — $ — $ 18,620 Total Assets at Fair Value $ 18,620 $ — $ — $ 18,620 The fair value of the investment securities at December 31, 2021 were as follows: Fair Value Measurements at December 31, 2021 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 26,842 $ — $ — $ 26,842 Total Assets at Fair Value $ 26,842 $ — $ — $ 26,842 The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2022 or 2021. The Company’s financial instruments consist primarily of cash and cash equivalents, accounts receivable and other receivables, accounts payable and accrued liabilities. For accounts receivable and other receivables, accounts payable and accrued liabilities, the carrying amounts of these financial instruments as of December 31, 2022 and December 31, 2021 were considered representative of their fair values due to their short term to maturity or repayment. Cash equivalents are carried at cost, which approximates their fair value. The Company’s Level 3 liabilities consist of a contingent liability resulting from the Anawah, Inc. ("Anawah") acquisition as described in Note 16, as well as preferred investment options related to the August 2022 Registered Direct Offering described in Note 14. As of December 31, 2021, the Company also had common stock warrant liabilities related to the March 2018, the June 2019, the September 2019, and the January 2021 Offerings, described in Note 14, which were reclassified to additional paid-in capital upon adoption of ASU 2020-06, as of January 1, 2022. See Note 3 for details of the adoption of ASU 2020-06. The contingent liability related to the Anawah acquisition was measured and recorded on a recurring basis as of December 31, 2022 and 2021, using unobservable inputs, namely the Company’s ability and intent to pursue certain specific products developed using technology acquired in the purchase. A significant deviation in the Company’s ability and/or intent to pursue the technology acquired in the purchase could result in a significantly lower (higher) fair value measurement. The preferred investment option liabilities were measured and recorded on a recurring basis using the Black-Scholes Model with the following assumptions at December 31, 2022: August 2022 Options August 2022 Placement Agent Options December 31, December 31, Expected term (in years) 4.67 4.67 Expected volatility 106.2 % 106.2 % Risk-free interest rate 4.0 % 4.0 % Expected dividend yield 0 % 0 % The significant unobservable input used in the fair value measurement of the Company’s Level 3 warrant liabilities is volatility. A significant increase (decrease) in volatility could result in a significantly higher (lower) fair value measurement. The following table sets forth the establishment of the Company’s Level 3 liabilities, as well as a summary of the changes in the fair value and other adjustments (in thousands): (Dollars in thousands) Common Stock Common Common Common August 2022 August 2022 Contingent Total Balance as of December 31, 2021 $ 7 $ 170 $ 223 $ 2,993 $ — $ — $ 2,070 $ 5,463 Reclassification upon adoption ( 7 ) ( 170 ) ( 223 ) ( 2,993 ) — — — ( 3,393 ) Initial recognition — — — — 3,824 191 — 4,015 Change in fair value and — — — — ( 3,057 ) ( 152 ) ( 70 ) ( 3,279 ) Balance as of December 31, 2022 $ — $ — $ — $ — $ 767 $ 39 $ 2,000 $ 2,806 The Company recorded aggregate impairment charges of $ 404,000 and $ 3.3 million during the years ended December 31, 2022 and 2021, respectively, related to intangible assets and other long-lived assets. The Company has classified the fair value measurements as a Level 3 measurement in the fair value hierarchy because they involve significant unobservable inputs such as cash flow projections, discount rates and management assumptions.

Arcadia Wellness Acquisition

Arcadia Wellness Acquisition	12 Months Ended
	Dec. 31, 2022
Arcadia Wellness Acquisition [Member]
Business Acquisition [Line Items]
Arcadia Wellness Acquisition	Note 7. Arcadia Wellness Acquisition On May 17, 2021, the Company’s wholly owned subsidiary Arcadia Wellness, acquired the assets of Eko, Lief, and Zola. The acquisition included consumer brands of bath and body care products such as Soul Spring, the CBD-infused botanical therapy brand, Saavy Naturals, a line of natural body care products and Provault, a CBD-infused sports performance formula. Also included in the purchase was Zola, a coconut water sourced from Thailand. The acquisition was recorded as a business combination, in accordance with ASC Topic 805. The purchase price consideration for the acquisition totaled an estimated $ 6.1 million, of which $ 4.0 million in cash and $ 2.1 million in the form of 20,686 shares of the Company’s common stock, was paid during the month of May 2021. The cash consideration paid for the acquisition was funded by cash on hand. Acquisition costs are not included as components of consideration transferred and instead are accounted for as expenses in the period in which the costs are incurred. The Company incurred costs related to the Arcadia Wellness acquisition of approximately $ 850,000 included in selling, general and administrative expenses in the Company's consolidated statements of operations and comprehensive loss for the year ended December 31, 2021. The following table presents the allocation of the purchase price of the assets acquired, based on their fair values at the acquisition date (in thousands): Purchase Price Inventory $ 840 Prepaid and other current assets 62 Fixed assets 308 Deposits 82 Customer list 360 Trade names and trademarks 2,900 Formulations 260 Goodwill 1,240 Total consideration allocated $ 6,052 The former shareholders of Eko, Lief, and Zola remain responsible for their pre-acquisition liabilities. In connection with the acquisition , the Company entered into a lease agreement for the use of offices, production equipment acquired, and storage warehouses. The lease was effective on May 17, 2021 and has a term of 3 years . For the period from January 1, 2022 to December 31, 2022, the Company recognized approximately $ 6.5 million of revenue and $ 2.1 million of net loss relating to Arcadia Wellness, which included charges related to the Radiance Beauty licensing agreement discussed below, as well as the amortization of acquired intangible assets. For the period from May 17 to December 31, 2021, the Company recognized approximately $ 4.3 million of revenue and $ 7.5 million of net loss relating to Arcadia Wellness, which included charges for the amortization and impairment of acquired intangible assets and goodwill. Acquired intangible assets of $ 3.5 million include trade names and trademarks of $ 2.9 million (indefinite useful life), customer list of $ 360,000 ( fifteen-year useful life) and formulations of $ 260,000 ( ten-year useful life). The total weighted average amortization period for the acquired intangibles is 12.9 years. The acquisition produced $ 1.2 million of goodwill. The goodwill is attributable to a combination of Arcadia Wellness’s expectation regarding a more meaningful engagement by the customers due to the scale of the combined Company, and other synergies. Goodwill will be tested for impairment at least annually (more frequently if certain indicators are present). Goodwill arising from the Arcadia Wellness acquisition is deductible for tax purposes. On July 8, 2022, the Company entered into a licensing agreement with Radiance Beauty. Under the terms of the licensing agreement, Radiance Beauty was granted an exclusive, transferable, sublicensable, perpetual, worldwide license to use the Saavy Naturals™ mark and to modify, manufacture, distribute, market and sell related products. In addition, as part of the licensing agreement, Radiance Beauty received the remaining accounts receivables and inventory balances after July 31, 2022, certain equipment, as well as three months of salaries in the amount of $ 355,000 and rent, maintenance and utilities in the amount of $ 19,000 . Radiance Beauty is subleasing space from the Company and will pay the Company a 4 % royalty of gross sales of products beginning January 1, 2023. During the year ended December 31, 2022, accounts receivables and inventories of $ 21,000 and $ 394,000 , respectively, were written down. In addition, property and equipment and intangible assets were written down by $ 320,000 and $ 72,000 , respectively, during the year ended December 31, 2022. Supplemental Pro-Forma Results of Operations (Unaudited) The following unaudited pro-forma consolidated results of operations for the years ended December 31, 2022 and 2021, have been prepared as if the acquisition of Arcadia Wellness had occurred on January 1, 2021 and includes adjustments for amortization of intangibles, and the addition to basic and diluted weighted average number of shares outstanding. For the year 2022 2021 Total revenues $ 9,956 $ 9,062 Net loss ( 15,605 ) ( 17,854 ) Net loss attributable to common stockholders $ ( 15,376 ) $ ( 16,380 ) Weighted average shares - Basic and diluted 599,389 539,773 Net loss per share attributable to common stockholders: Basic and diluted $ ( 25.65 ) $ ( 30.35 )

Intangible Assets, Net

Intangible Assets, Net	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, Net	Note 8. Intangible assets, net The Company’s intangible assets, net as of December 31, 2022 and 2021, consist of the following (in thousands): December 31, 2022 December 31, 2021 Gross Accumulated Amortization Net Carrying Gross Accumulated Amortization Net Carrying Amortized intangible assets Intellectual property $ 144 $ 141 $ 3 $ 570 $ 419 $ 151 Customer lists 33 31 2 400 355 45 Total amortizable intangible assets $ 177 $ 172 $ 5 $ 970 $ 774 $ 196 Indefinite-lived intangible assets Brands and trademarks $ 35 $ — $ 35 $ 2,950 $ 2,662 $ 288 Total intangible asset, net $ 212 $ 172 $ 40 $ 3,920 $ 3,436 $ 484 (1) During the years ended December 31, 2022 and 2021, the Company estimated an overall decrease in the sales forecast for AW products, due to an inventory item rationalization, in addition to a decrease in the sales forecast of ISI seeds, related to the saturated hemp seed market. As a result, Arcadia performed a quantitative intangible assets impairment test. The Company used a discounted cash flow approach to develop the fair value of our acquired intellectual property, customer lists, brands and trademarks. As a result of this assessment, Arcadia recorded an impairment of intangible assets in the amount of $ 404,000 and $ 3.3 million in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2022 and 2021, respectively. Of the impairment recognized during the year ended December 31, 2022, $ 72,000 was related to the Radiance Beauty licensing agreement.

Consolidated Joint Venture

Consolidated Joint Venture	12 Months Ended
	Dec. 31, 2022
Equity Method Investments and Joint Ventures [Abstract]
Consolidated Joint Venture	Note 9. Consolidated Joint Venture On August 9, 2019, the Company and Legacy Ventures Hawaii, LLC, a Nevada limited liability company (“Legacy”), formed Archipelago Ventures Hawaii, LLC, a Delaware limited liability company and entered into a Limited Liability Company Operating Agreement (the “Operating Agreement”). The Company and Legacy formed Archipelago to develop, extract and commercialize hemp-derived products from industrial hemp grown in Hawaii. Pursuant to the Operating Agreement, a joint operating committee consisting of two individuals appointed by the Company and two individuals appointed by Legacy will manage Archipelago. As of December 31, 2022, the Company and Legacy hold 50.75 % and 49.25 % interests in Archipelago, respectively, and have made capital contributions to Archipelago of $ 3.1 million and $ 3.0 million, respectively, as determined by the joint operating committee. The Operating Agreement includes indemnification rights, non-competition obligations, and certain rights and obligations in connection with the transfer of membership interests, including rights of first refusal. The Company consolidates Archipelago in the consolidated financial statements after eliminating intercompany transactions. Net loss attributable to non-controlling interest of $ 236,000 and $ 1.5 million was recorded as an adjustment to net loss to arrive at net loss attributable to common stockholders for the years ended December 31, 2022 and 2021, respectively. Legacy’s equity interests are presented as non-controlling interests on the consolidated balance sheets. Refer to Note 2 for basis of presentation. In October 2021, Arcadia and Legacy mutually agreed to wind down the cultivation activities of Archipelago, due to regulatory challenges and a saturated hemp market.

Verdeca-BIOX Transactions

Verdeca-BIOX Transactions	12 Months Ended
	Dec. 31, 2022
Equity Method Investments and Joint Ventures [Abstract]
Verdeca-BIOX Transactions	Note 10. Verdeca-BIOX Transactions In February 2012, the Company formed Verdeca, which was equally owned with Bioceres. Verdeca was formed to develop and deregulate soybean varieties using both partners’ agricultural technologies. On November 12, 2020, the Company entered into a Master Transaction Agreement with BIOX pursuant to which (i) the Company sold all of its memberships interests it owned in Verdeca to BIOX, and (ii) the Company and BIOX entered into a license agreement for certain intellectual property rights, including rights to the Company’s Haab 4 ("HB4") soybean trait and its GoodWheat portfolio of specialty wheat products in South and Central America. Prior to the transaction, Verdeca was equally owned by the Company and a wholly-owned subsidiary of BIOX. In consideration for the sale of the membership interests in Verdeca and entering into the license agreement, on November 12, 2020, BIOX paid the Company $ 5,000,000 in cash and issued the Company 1,875,000 shares of BIOX common stock. BIOX also paid the Company an additional $ 1,000,000 for transaction expenses and fees and is obligated to pay $ 2,000,000 in four equal quarterly payments with the first payment commencing within thirty days of either BIOX reaching commercial plantings of at least 200,000 hectares of HB4 soybeans or China approving the HB4 soybean trait for “food and feed”. In addition to the above payments, BIOX is also obligated to pay the Company quarterly royalty payments equal to six percent ( 6 %) of the net revenues BIOX or its affiliates receive from HB4 soybean sales and twenty five percent ( 25 %) of the net revenues BIOX or its affiliates receive from sales of licensed wheat products; provided that total royalty payments for HB4 soybeans shall not exceed $ 10,000,000 . The total amount of fixed consideration agreed upon as of the date of the transaction was $ 16,968,750 . The fixed consideration was allocated based on estimates of the stand-alone selling prices. A fixed consideration in the amount of $ 10,288,000 , including $ 6,650,000 of corporate securities received, was allocated to the sale of the membership interest in Verdeca and resulted in a gain of $ 8,814,000 in 2020. Inventory with a carrying value of $ 1,474,000 was derecognized in connection with the sale of the membership interest in Verdeca. A fixed consideration in the amount of $ 6,680,000 , including $ 4,318,000 of corporate securities received, has been allocated to the sale of intellectual property rights and was recorded as license revenues in 2020. Any future proceeds from the agreement will be allocated in the same proportion. All of the shares of BIOX were sold in June 2021 and generated a one-time impact on liquidity in the amount of $ 22.2 million of gross proceeds. See Note 6. During the second quarter of 2022, Bioceres received China's approval of the HB4 soybean trait and as a result, Arcadia recorded license revenue of $ 862,000 and a gain on sale of Verdeca of $ 1.1 million on the consolidated statements of operations and comprehensive loss. As of December 31, 2022, the Company received payment of $ 1.0 million with the remaining $ 1.0 million in accounts receivable and other receivables, which the Company anticipates to receive over the next three months pursuant to the agreement.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	Note 11. Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consisted of the following (in thousands): As of December 31, 2022 2021 Accounts payable - trade $ 931 $ 1,411 Payroll and benefits 1,373 1,606 Inventory 69 72 Royalty fees due to unrelated parties 6 51 Consulting 8 79 Rent and utilities 28 127 Audit and tax fees 99 72 Legal 69 58 Other 298 162 Total accounts payable and accrued expenses $ 2,881 $ 3,638

Collaborative Arrangements

Collaborative Arrangements	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborative Arrangements	Note 12. Collaborative Arrangements In August 2017 , the Company entered into a collaborative arrangement for the research, development and commercialization of an improved wheat quality trait in North America. This collaborative arrangement is a contractual agreement with Corteva AgriScience (“Corteva”) and involves a joint operating activity where both Arcadia and Corteva are active participants in the activities of the collaboration. Arcadia and Corteva participate in the research and development, and Arcadia has the primary responsibility for the intellectual property strategy while Corteva will generally lead the marketing and commercialization efforts. Both parties are exposed to significant risks and rewards of the collaboration and the agreement includes both cost sharing and profit sharing. The activities are performed with no guarantee of either technological or commercial success. The Company accounts for research and development (“R&D”) costs in accordance ASC 730, Research and Development , which states R&D costs must be charged to expense as incurred. Accordingly, internal R&D costs are expensed as incurred. Third-party R&D costs are expensed when the contracted work has been performed or as milestone results are achieved.

Equity Financing

Equity Financing	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Equity Financing	Note 13. Equity Financing Private Placements In January 2021, the Company issued in a private placement offering (the “January 2021 Private Placement”) pursuant to a securities purchase agreement (“January 2021 Purchase Agreement”) (i) 196,920 shares of its common stock, and (ii) warrants to purchase up to 98,460 shares of common stock at an exercise price of $ 125.20 per share (the “January 2021 Warrants”) and raised total gross proceeds of $ 25.1 million. The January 2021 Warrants are exercisable at any time at the option of the holder and expire 5.5 years from the date of issuance. In connection with the January 2021 Private Placement, the Company granted to a placement agent warrants to purchase a total of 9,846 shares of Common Stock (the “January 2021 Placement Agent Warrants”) that have an exercise price per share equal to $ 159.60 and a term of 5.5 years from the date of issuance. The common stock warrants are classified as a liability within Level 3 due to a contingent cash payment feature. The Company utilized the Black Scholes Merton model on January 28, 2021 with the following assumptions: volatility of 123.8 %, stock price of $ 115.20 and risk-free rate of 0.5 %. The estimated fair value of the common stock warrant liability was subsequently remeasured at December 31, 2021 with the changes recorded on the Company’s consolidated statements of operations and comprehensive loss. The January 2021 Placement Agent Warrants were issued for services performed by the placement agent as part of the January 2021 Private Placement and were treated as offering costs. The value of the January 2021 Placement Agent Warrants was determined to be $ 942,000 , calculated using the Black-Scholes Model. The Company incurred additional offering costs totaling $ 1.9 million that consist of direct incremental legal, advisory, accounting and filing fees relating to the January 2021 Private Placement. The offering costs, inclusive of the January 2021 Placement Agent Warrants, totaled $ 2.8 million and allocated to the common stock warrant liability and the common stock using their relative fair values. A total of $ 769,000 was allocated to the common stock warrant liability and expensed and the remaining $ 2.0 million was allocated to the common stock and offset to additional paid in capital. In March 2018, the Company issued in a private placement offering (the “March 2018 Private Placement”) pursuant to a securities purchase agreement (“March 2018 Purchase Agreement”) (i) 7,519 shares of its common stock and (ii) warrants to purchase up to 7,519 shares of common stock at an initial exercise price equal to $ 1,830.00 (the “March 2018 Warrants”) and raised total gross proceeds of $ 10.0 million. The March 2018 Warrants are exercisable at any time at the option of the holder and expire five years from the date of issuance. In connection with the March 2018 Private Placement, the Company granted to a placement agent warrants to purchase a total of 376 shares of Common Stock (the “March 2018 Placement Agent Warrants”) that have an exercise price per share equal to $ 1,662.50 and a term of five years from the date of issuance. The number of shares of common stock and the number and exercise price of the March 2018 Warrants issued in the March 2018 Private Placement were subject to adjustments as provided in the March 2018 Purchase Agreement. Following the adjustments as provided in the March 2018 Purchase Agreement, the number of shares issued to the purchasers was 30,041 , the total number of shares issuable upon exercise of the March 2018 Warrants was 32,071 and the per share exercise price of the March 2018 Warrants was $ 429.03 . Registered Direct Offerings On May 11, 2018, the Company filed a shelf Registration Statement on Form S-3 with the SEC which was declared effective on June 8, 2018 (“2018 Shelf Registration Statement”). On April 21, 2022, the Company filed a shelf Registration Statement on Form S-3 with the SEC which was declared effective on May 12, 2022 (“2022 Shelf Registration Statement”). Each of the 2018 Shelf Registration Statement and the 2022 Shelf Registration Statement allows the Company to sell any combination of common stock, preferred stock, warrants and units consisting of such securities in one or more offerings from time to time having aggregate offering prices of up to $ 50.0 million. The Company ceased being able to use the 2018 Shelf Registration Statement to register the issuance of securities after June 8, 2021, the three-year anniversary of its effective date. The 2022 Shelf Registration Statement may no longer be used to register the issuance of securities after May 12, 2025, the three-year anniversary of its effective date. In August 2022, the Company entered into a securities purchase agreement (the “August 2022 Purchase Agreement”) pursuant to which it sold (i) 61,250 registered shares of its common stock, pursuant to the 2022 Shelf Registration Statement, (ii) pre-funded common stock purchase warrants (the “Pre-Funded Warrants”) to purchase up to 56,813 shares of common stock, at an exercise price of $ 0.004 per share, which Pre-Funded Warrants were registered under the 2022 Shelf Registration Statement, and (iii) unregistered preferred investment options (the "August 2022 Options") to purchase up to 118,063 shares of common stock, at an exercise price of $ 37.35 per share, in a private placement, for total gross proceeds of $ 5.0 million (the “August 2022 Registered Direct Offering”). The August 2022 Registered Direct Offering closed on August 16, 2022 . The August 2022 Pre-Funded Warrants became exercisable upon issuance and are exercisable until exercised in full. The August 2022 Options became exercisable upon issuance and expire 5 years after the date of issuance. In connection with the August 2022 Registered Direct Offering, the Company granted to a placement agent preferred investment options ("August 2022 Placement Agent Options") to purchase a total of 5,904 shares of common stock that have an exercise price per share equal to $ 52.80 and a term of five years . The August 2022 Options and August 2022 Placement Agent Options are classified as liabilities within Level 3 due to a certain early settlement provisions that preclude them from equity classification. The Company utilized the Black-Scholes Merton model on August 16, 2022 with the following assumptions: volatility of 128.46 %, stock price of $ 37.60 , risk-free rate of 2.97 % and a term of 5 years. The estimated fair value of the common stock option liabilities was subsequently remeasured at December 31, 2022 with the changes recorded on the Company’s consolidated statements of operations and comprehensive loss. The August 2022 Placement Agent Options were issued for services performed by the placement agent as part of the August 2022 Registered Direct Offering and were treated as offering costs. The value of the August 2022 Placement Agent Options was determined to be $ 191,000 , calculated using the Black-Scholes Model. The Company incurred additional offering costs totaling $ 488,000 that consist of direct incremental legal, advisory, accounting and filing fees relating to the August 2022 Registered Direct Offering. The offering costs, inclusive of the August 2022 Placement Agent Options, totaled $ 679,000 and were allocated to the common stock option liabilities, the common stock and Pre-Funded Warrants using their relative fair values. A total of $ 314,000 was allocated to the common stock option liabilities and expensed while the remaining $ 365,000 was allocated to the common stock and Pre-Funded Warrants and offset to additional paid in capital. In December 2020, the Company entered into a securities purchase agreement (the “December 2020 Purchase Agreement”) pursuant to which it sold (i) 65,467 registered shares of its common stock pursuant to the 2018 Shelf Registration Statement and (ii) unregistered warrants to purchase 65,467 shares of its common stock (the “December 2020 Warrants”) in a private placement, for total gross proceeds of $ 8.0 million (the “December 2020 Registered Direct Offering”). The December 2020 Registered Direct Offering closed on December 22, 2020 . The December 2020 Warrants have an exercise price of $ 120.00 per share, became exercisable upon issuance and expire 5.5 years after the date of issuance. In connection with the December 2020 Registered Direct Offering, the Company granted to a placement agent warrants to purchase a total of 3,274 shares of common stock (“December 2020 Placement Agent Warrants”) that have an exercise price per share equal to $ 152.75 and a term of five years . In September 2019, the Company entered into a securities purchase agreement (the “September 2019 Purchase Agreement”) pursuant to which it sold (i) 32,971 registered shares of its common stock pursuant to the 2018 Shelf Registration Statement and (ii) unregistered warrants to purchase 16,486 shares of its common stock (the “September 2019 Warrants”) in a private placement, for total gross proceeds of $ 10.0 million (the “September 2019 Registered Direct Offering”). The September 2019 Registered Direct Offering closed on September 5, 2019 . The September 2019 Warrants have an exercise price of $ 300.80 per share, became exercisable upon issuance and expire 5.5 years after the date of issuance. In connection with the September 2019 Registered Direct Offering, the Company granted to a placement agent warrants to purchase a total of 1,649 shares of common stock (“September 2019 Placement Agent Warrants”) that have an exercise price per share equal to $ 379.12 and a term of five years . In June 2019, the Company entered into a securities purchase agreement (the “June 2019 Purchase Agreement”) pursuant to which it sold (i) 37,240 registered shares of its common stock pursuant to the 2018 Shelf Registration Statement and (ii) unregistered warrants to purchase 37,240 shares of its common stock (the “June 2019 Warrants”) in a private placement, for total gross proceeds of $ 7.5 million (the “June 2019 Registered Direct Offering”). The June 2019 Registered Direct Offering closed on June 14, 2019 . The June 2019 Warrants have an exercise price of $ 200.00 per share, became exercisable upon issuance and expire 5.5 years after the date of issuance. In connection with the June 2019 Registered Direct Offering, the Company granted to a placement agent warrants to purchase a total of 1,862 shares of common stock (“June 2019 Placement Agent Warrants”) that have an exercise price per share equal to $ 251.75 and a term of five years . In June 2018, the Company entered into a securities purchase agreement (the “June 2018 Purchase Agreement”) pursuant to which it sold (i) 34,809 registered shares of its common stock pursuant to the 2018 Shelf Registration Statement and (ii) unregistered warrants to purchase 34,809 shares of its common stock (the “June 2018 Warrants”) in a private placement, for total gross proceeds of $ 14.0 million (the “June 2018 Registered Direct Offering”). The June 2018 Registered Direct Offering closed on June 14, 2018 . The June 2018 Warrants have an exercise price of $ 397.60 per share, became exercisable upon issuance and expire 5.5 years after the date of issuance. In connection with the June 2018 Registered Direct Offering, the Company granted to a placement agent warrants to purchase a total of 1,741 shares of common stock (“June 2018 Placement Agent Warrants”) that have an exercise price per share equal to $ 502.72 and a term of five years .

Warrants and Options

Warrants and Options	12 Months Ended
	Dec. 31, 2022
Warrants and Rights Note Disclosure [Abstract]
Warrants and Options	Note 14. Warrants and Options Equity Classified Common Stock Warrants In connection with professional services agreements with non-affiliated third parties, during the year ended December 31, 2022, the Company issued service and performance warrants (“Service and Performance Warrants”). The Company issued the following warrants to purchase shares of its common stock, which are outstanding as of December 31, 2022 and 2021, respectively. These warrants are exercisable any time at the option of the holder until their expiration date. Issuance Date Term Exercise Warrants Warrants Warrants Warrants December 2022 Service and Performance Warrants (1) December 2022 5 years $ 11.20 — — — 1,000 October 2022 Service and Performance Warrants (1) October 2022 5 years $ 16.00 — — — 1,000 August 2022 Pre-Funded Warrants August 2022 perpetual $ — — — — 56,813 January 2021 Placement Agent Warrants January 2021 5.5 years $ 159.60 — 9,846 — 9,846 January 2021 Service and Performance Warrants (1) January 2021 2 years $ 123.20 — 188 — 188 December 2020 Warrants December 2020 5.5 years $ 120.00 — 65,467 — 65,467 December 2020 Placement Agent Warrants December 2020 5 years $ 152.80 — 3,274 — 3,274 July 2020 Warrants July 2020 5.5 years $ 154.00 — 16,036 — 16,036 July 2020 Placement Agent Warrants July 2020 5.5 years $ 198.80 — 802 — 802 May 2020 Warrants May 2020 5 years $ 191.20 — 34,809 — 34,809 May 2020 Placement Agent Warrants May 2020 5 years $ 245.20 — 1,741 — 1,741 March 2020 Service and Performance Warrants (1) March 2020 3 years $ 100.00 — 459 — 459 February 12, 2020 Service and Performance Warrants (1)(3) February 2020 2 years $ 188.40 — 3,750 — — February 3, 2020 Service and Performance Warrants (1)(3) February 2020 2 years $ 196.40 — 250 — — September 2019 Placement Agent Warrants September 2019 5 years $ 379.20 — 1,649 — 1,649 June 2019 Placement Agent Warrants June 2019 5 years $ 251.60 — 1,862 — 1,862 April 2019 Service and Performance Warrants (1) April 2019 5 years $ 247.20 — 3,629 — 3,629 June 2018 Placement Agent Warrants June 2018 5 years $ 502.80 — 1,741 — 1,741 March 2018 Placement Agent Warrants March 2018 5 years $ 1,662.40 — 376 — 376 January 2021 Warrants (2) January 2021 5.5 years $ 125.20 — 98,460 — 98,460 September 2019 Warrants (2) September 2019 5.5 years $ 300.80 — 16,486 — 16,486 June 2019 Warrants (2) June 2019 5.5 years $ 200.00 — 10,896 — 10,896 June 2018 Warrants (2) June 2018 5.5 years $ 397.60 — — — — March 2018 Warrants (2) March 2018 5 years $ 429.20 — 16,036 — 16,036 Total — 287,757 — 342,570 (1) The Company issued service and performance warrants (“Service and Performance Warrants”) in connection with professional services agreements with non-affiliated third party entities. (2) Certain warrants contain a contingent cash payment feature and therefore were accounted for as a liability at the date of issuance and were adjusted to fair value at each balance sheet date. Upon adoption of ASU No. 2020-06 on January 1, 2022, all of the common stock warrant liabilities have been reclassified to equity classified common stock warrants, due to the elimination of the contingent cash payments as criteria for liability classification. (3) These warrants expired in February 2022 . Liability Classified Preferred Investment Options The preferred investment options issued in connection with the August 2022 Registered Direct Offering contain certain early settlement provisions that preclude them from equity classification and therefore were accounted for as liabilities at the date of issuance and are adjusted to fair value at each balance sheet date. The change in fair value of the options liabilities is recorded as change in fair value of common stock warrant and option liabilities in the consolidated statements of operations and comprehensive loss. The key terms and activity of the liability classified preferred investment options are summarized as follows: Issuance Date Term Exercise Exercised Outstanding at Exercised Outstanding at August 2022 Options August 2022 5 years $ 37.20 — — — 118,063 August 2022 Placement Agent Options August 2022 5 years $ 52.80 — — — 5,904 Total — — — 123,967 See Note 6 for the Black-Scholes option-pricing model and weighted-average assumptions used to estimate the fair value of the preferred investment options liabilities.

Stock-Based Compensation and Em

Stock-Based Compensation and Employee Stock Purchase Program	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation and Employee Stock Purchase Program	Note 15. Stock-Based Compensation and Employee Stock Purchase Program Stock Incentive Plans The Company has two equity incentive plans: the 2006 Stock Plan (“2006 Plan”) and the 2015 Omnibus Equity Incentive Plan (“2015 Plan”). In 2006, the Company adopted the 2006 Plan, which provided for the granting of stock options to executives, employees, and other service providers under terms and provisions established by the Board of Directors. The Company granted non-statutory stock options (“NSOs”) under the 2006 Plan until May 2015, when it was terminated as to future awards, although it continues to govern the terms of options that remain outstanding and were issued under the 2006 Plan. The 2015 Plan became effective upon the Company’s IPO in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 3,860 shares of common stock reserved for future issuance, which included 259 that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan. The 2015 Plan provides for the grant of incentive stock options (“ISOs”), NSOs, restricted stock awards, stock units, stock appreciation rights, and other forms of equity compensation, all of which may be granted to employees, officers, non-employee directors, and consultants. The exercise price for ISOs and NSOs will be granted at a price per share not less than the fair value of our common stock at the date of grant. Options granted generally vest over a four-year period; however, there might be alternative vesting schedules, as approved by the Board. Options granted, once vested, are generally exercisable for up to 10 years, after grant to the extent vested. In June 2019, the shareholders approved an amendment to the Company’s 2015 Plan for a one-time increase to the number of shares of common stock that may be issued under the 2015 Plan by 3,000 shares. On May 17, 2021, upon completion of the Arcadia Wellness transaction, the Company granted 6,200 inducement stock option pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. On May 28, 2021, the Company filed a registration statement on Form S-8 to register the issuance of shares upon exercise of these inducement stock options. On February 2, 2022, Stanley Jacot, Jr. was hired as the new president and chief executive officer of the Company. The Company granted Mr. Jacot an inducement stock option to purchase 7,902 shares of the Company’s common stock pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The Company has filed a registration statement on Form S-8 to register the issuance of shares upon exercise of this inducement stock option. The inducement options grants have been issued outside of the 2015 Plan, but are subject to the terms and conditions of the 2015 Plan. As of December 31, 2022, a total of 62,192 shares of common stock were reserved for issuance under the 2015 Plan, of which 10,771 shares of common stock are available for future grant. As of December 31, 2022, a total of 103 and 51,421 options are outstanding under the 2006 and 2015 Plans, respectively. As of December 31, 2021, a total of 206 and 33,648 options were outstanding under the 2006 and 2015 Plans, respectively. As of December 31, 2022 a total of 8,477 inducement options are outstanding. The following is a summary of stock option information and weighted average exercise prices under the Company’s stock incentive plans (in thousands, except share data and price per share): Shares Weighted- Aggregate Outstanding — Balance at December 31, 2020 22,243 $ 578.40 $ 9,600 Options granted 30,676 110.40 — Options exercised — — — Options forfeited ( 11,004 ) 123.60 43,440 Options expired ( 6,361 ) 1,160.80 — Outstanding — Balance at December 31, 2021 35,554 211.20 — Options granted 33,408 44.00 11,880 Options exercised — — — Options forfeited ( 6,658 ) 91.60 — Options expired ( 2,302 ) 644.80 — Outstanding — Balance at December 31, 2022 60,002 114.80 — Vested and expected to vest — December 31, 2022 54,018 121.60 — Exercisable —December 31, 2022 22,456 $ 215.20 $ — Aggregate intrinsic value represents the difference between the exercise price of the options and the estimated fair value of the Company’s common stock determined by our Board of Directors for each of the respective periods. The intrinsic value of options exercisable was $ 0 for both years ended December 31, 2022 and 2021. As of December 31, 2022, there was $ 1.1 million of unrecognized compensation cost related to unvested stock-based compensation grants that will be recognized over the weighted-average remaining recognition period of 2.4 years. On December 14, 2021, Matt Plavan provided notice to the Company of his resignation as Arcadia’s president, chief executive officer and director, effective as of December 31, 2021. On December 19, 2021, Arcadia and Mr. Plavan entered into a Separation and Release Agreement (the “Separation Agreement”) which provided that the vesting of all unvested options previously issued to Mr. Plavan accelerated pursuant to the terms of the Separation Agreement. In addition, the Separation Agreement extends the post-termination exercise period of the accelerated options from 90 days to up to two and one-half years . The stock compensation expense related to the modification of Mr. Plavan’s stock options was $ 154,000 and recognized in selling, general and administrative expenses during the year ended December 31, 2021. In determining the fair value of the stock-based awards, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine. Expected Term— The expected term is the estimated period of time outstanding for stock options granted and was estimated based on a simplified method allowed by the SEC, and defines the term as the average of the contractual term of the options and the weighted-average vesting period for all open employee awards. Expected Volatility— The historical volatility data was computed using the daily closing prices for the Company’s shares during the equivalent period of the calculated expected term of the stock-based awards. Risk-Free Interest Rate— The risk-free interest rate is based on the interest rate of U.S. Treasuries of comparable maturities on the date the options were granted. Expected Dividend— The expected dividend yield is based on the Company’s expectation of future dividend payouts to common stockholders. The fair value of stock option awards was estimated at the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumption: Year Ended December 31, Assumptions 2022 2021 Expected term (years) 6.40 6.31 Expected volatility 122 % 121 % Risk-free interest rate 2.61 % 0.86 % Expected dividend yield — — The weighted-average, estimated grant date fair value of employee stock options granted during the years ended December 31, 2022 and 2021 was $ 38.50 and $ 96.40 , respectively. The Company recognized $ 1.1 million and $ 1.5 million of compensation expense for stock options awards for the years ended December 31, 2022 and 2021, respectively. Employee Stock Purchase Plan The Company’s 2015 Employee Stock Purchase Plan (“ESPP”) became effective on May 14, 2015. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount of up to 15 % of their eligible compensation through payroll deductions, subject to any plan limitations. After the first offering period, which began on May 14, 2015 and ended on February 1, 2016 , the ESPP provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at 85 % of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last day of the offering period. As of December 31, 2022 , the number of shares of common stock reserved for future issuance under the ESPP is 3,122 . The ESPP provides for automatic annual increases in the shares available for purchase beginning on January 1, 2016. As of December 31, 2022 , 1,475 shares had been issued under the ESPP. The Company recorded $ 4,000 and $ 14,000 of ESPP related compensation expense for the years ended December 31, 2022 and 2021 , respectively.

Commitment and Contingencies

Commitment and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 16. Commitments and Contingencies Leases The Company leases office and facility space having initial lease terms ranging from one to five years , including certain renewal options available to the Company at market rates. See Note 17. Legal Matters From time to time, in the ordinary course of business, the Company may become involved in certain legal proceedings. The Company currently is not a party to any material litigation or other material legal proceedings. Contingent Liability Related to the Anawah Acquisition On June 15, 2005 , the Company completed its agreement and plan of merger and reorganization with Anawah, Inc. (“Anawah”), to purchase the Anawah’s food and agricultural research company through a non-cash stock purchase. Pursuant to the merger with Anawah, and in accordance with the ASC 805 - Business Combinations, the Company incurred a contingent liability not to exceed $ 5.0 million. This liability represents amounts to be paid to Anawah’s previous stockholders for cash collected on revenue recognized by the Company upon commercial sale of certain specific products developed using technology acquired in the purchase. As of December 31, 2010, the Company ceased activities relating to three of the six Anawah product programs thus, the contingent liability was reduced to $ 3.0 million. In 2016, one of the programs previously accrued for was abandoned and another program previously abandoned was reactivated. During the fourth quarter of 2019, the Company determined that one of the technologies was no longer active and decided to abandon the previously accrued program. As of December 31, 2022, the Company continues to pursue or are otherwise liable for a total of two development programs using this technology and believes that the contingent liability is probable. As a result, $ 2.0 million remains on the consolidated balance sheet as an other noncurrent liability. Contingent Liability Related to the ISI Acquisition In August 2020, the Company acquired by merger Industrial Seed Innovations (ISI). A portion of the purchase price consideration for the acquisition in the amount of $ 280,000 was to be recognized in two annual installments, each of up to 3,316 shares of the Company’s common stock, subject to the achievement of revenue milestones in 2021 and 2022. The contingent consideration of $ 280,000 was measured and recorded at fair value. During the years ended December 31, 2022 and 2021, a decrease in the liability of $ 70,000 and $ 210,000 was recorded, respectively, as a result of a remeasurement of the contingent consideration and reflected in changes in fair value of the contingent consideration on the consolidated statements of operations and comprehensive loss. Contracts The Company has entered into contract research agreements with unrelated parties that require the Company to pay certain funding commitments. The initial terms of these agreements range from one to three years in duration and in certain cases are cancelable. The Company licenses certain technologies via executed agreements (“In-Licensing Agreements”) that are used to develop and advance the Company’s own technologies. The Company has entered into various In-Licensing Agreements with related and unrelated parties that require the Company to pay certain license fees, royalties, and/or milestone fees. In addition, certain royalty payments ranging from 2 % to 15 % of net revenue amounts as defined in the In-Licensing Agreements are or will be due. Royalties due to both related and unrelated parties accrued as of December 31, 2022 and 2021 were $ 54,000 and $ 115,000 , respectively. Accrued royalties are included within accounts payable and accrued expenses on the consolidated balance sheets. Milestone payments are contingent upon the successful development or implementation of various technologies. During the year ended December 31, 2022, we recognized a milestone achievement of $ 2.0 million related to the regulatory approval of the HB4 soybean trait licensed to Biocere's. See Note 10 for more information. The Company could be adversely affected by certain actions by the government as it relates to government contract revenue received in prior years. Government agencies, such as the Defense Contract Audit Agency routinely audit and investigate government contractors. These agencies review a contractor’s performance under its agreements; cost structure; and compliance with applicable laws, regulations and standards. The agencies also review the adequacy of, and a contractor’s compliance with, its internal control systems and policies, including the contractor’s purchasing, property, estimating, compensation and management information systems. While the Company’s management anticipates no adverse result from an audit, should any costs be found to be improperly allocated to a government agreement, such costs will not be reimbursed, or if already reimbursed, may need to be refunded. If an audit uncovers improper or illegal activities, civil and criminal penalties and administrative sanctions, including termination of contracts, forfeiture of profits, suspension of payments or fines, and suspension or prohibition from doing business with the government could occur. In addition, serious reputational harm or significant adverse financial effects could occur if allegations of impropriety were made against the Company. There currently are routine audits in process relating to government grant revenues.

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Lessee Disclosure [Abstract]
Leases	Note 17. Leases Operating Leases As of December 31, 2022, the Company leases office space in Dallas, Texas and Davis, California, as well as additional buildings, land and equipment. Leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these short-term leases on a straight-line basis. The Company subleases a portion of the Davis office lease to third parties. In May 2022, the Company terminated its lease for office space in Chesterfield, MO effective September 30, 2022. The original lease term was scheduled to expire in May 2024 . As a result, the Company paid $ 47,000 in early termination fees to exit the lease. In addition, the Company subleased the facility in Chatsworth, CA to Radiance Beauty as part of the licensing agreement beginning November 1, 2022 for the remainder of the lease term. During the year ended December 31, 2022, the Company entered into an agreement to lease office space in Dallas, Texas. The new lease commenced in July 2022. Some leases (the Davis and Dallas offices, a warehouse, and a copy machine) include one or more options to renew , with renewal terms that can extend the lease term from one to six years . The exercise of lease renewal options is at the Company’s sole discretion. During 2020, the Company entered into a lease amendment that provided for additional office space in Davis, CA, and extended the term through April 2025, with one option to renew for an additional five-year term. The Company initially expected to exercise its options to renew, and in accordance with ASC 842, Leases , accounted for the amendment and expected renewal as a lease modification and remeasured the operating lease liability. During the year ended December 31, 2021, the Company re-assessed its long-term strategy regarding office spaces, and determined that the expectation to exercise its option to renew for an additional five-year term after April 2025 is no longer reasonable. In accordance with ASC 842, the Company accounted for the change that resulted in a decrease of $ 2.8 million for the operating lease liability and of $ 2.6 million for the right of use asset. The Company’s lease agreements do not contain any material variable lease payments, material residual value guarantees or material restrictive covenants. Leases consisted of the following (in thousands): Leases Classification December 31, 2022 December 31, 2021 Assets Operating lease assets Right of use asset $ 1,848 $ 3,081 Total leased assets $ 1,848 $ 3,081 Liabilities Current - Operating Operating lease liability - current $ 1,010 $ 1,074 Noncurrent - Operating Operating lease liability - noncurrent 1,007 2,220 Total leased liabilities $ 2,017 $ 3,294 Lease Cost Classification For the For the Operating lease cost SG&A and R&D Expenses $ 1,028 $ 1,352 Short term lease cost (1) SG&A and R&D Expenses 6 133 Sublease income (2) SG&A and R&D Expenses ( 384 ) ( 63 ) Net lease cost $ 650 $ 1,422 (1) Sh ort term lease cost consists of field trial lease agreements with a lease term of 12 months or less. (2) Sublease income is recorded as a reduction to lease expense. Lease Term and Discount Rate December 31, 2022 December 31, 2021 Weighted-average remaining 2.4 2.7 Weighted-average discount rate 6 % 6 % The maturities of the operating lease liabilities as of December 31, 2022 are as follows (in thousands): Years Ending December 31, Amounts 2023 $ 1,104 2024 886 2025 156 2026 and thereafter — Total operating lease payments $ 2,146 Less: imputed interest 129 Total current and noncurrent operating lease liabilities $ 2,017

Debt

Debt	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Debt	Note 18. Debt Paycheck Protection Program Note On April 16, 2020, the Company borrowed $ 1.1 million through MidFirst Bank, a federally chartered savings association (the "Lender"), and entered into a promissory note for the same amount under the Paycheck Protection Program (“PPP”) that was established under the Coronavirus Aid Relief, and Economic Security Act (“CARES Act”) of 2020. During 2021, the Company applied for full PPP loan forgiveness, and in August 2021, the lender notified Arcadia that the Small Business Administration had forgiven the original loan in full. During the year ended December 31, 2021, the amount forgiven has been recorded as gain on extinguishment of PPP loan on the consolidated statements of operations and comprehensive loss, as the Company has been legally released from being the primary obligor in accordance with ASC 405-20, Liabilities – Extinguishment of Liabilities . Promissory Note On June 26, 2020 , the Company executed a promissory note (the “Note") in the amount of $ 2.0 million, payable to MidFirst Bank, a federally chartered savings association (the "Lender"). The Note was issued in accordance with the terms of a Loan Agreement dated as of May 18, 2020 entered into by the Company and the Lender (the “Loan Agreement”) in which the Lender agreed to make advances to the Company from time to time, at any amount up to but not to exceed $ 2.0 million. Pursuant to the Loan Agreement, the Note accrued interest, adjusted monthly, at a rate equal to the greater of (i) 3.25 % and (ii) the sum of (a) the quotient of the LIBOR Index divided by (one minus the reserve requirement set by the Federal Reserve), and (b) 2.50 %. The Company was required to make monthly interest payments on the Note to the Lender and pay the full principal amount plus any accrued but unpaid interest outstanding under the Note no later than May 18, 2023 . The Company and the Lender also entered into a Pledge and Security Agreement dated as of May 18, 2020 whereby the Company agreed to secure the Note by granting a security interest to the Lender for the Company’s deposit account held with and controlled by the Lender. On February 26, 2021, the Company repaid the full balance of $ 2.0 million, and on March 31, 2021, the line of credit was closed. As of December 31, 2021, there was no outstanding balance of the Note.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Note 19. Income Taxes The components of loss before income taxes are as follows (in thousands): Year Ended December 31, 2022 2021 Domestic $ ( 15,598 ) $ ( 16,006 ) Foreign — ( 126 ) Loss before income taxes $ ( 15,598 ) $ ( 16,132 ) The total income tax expense for the years ended December 31, 2022 and 2021 was $ 14,000 and $ 2,000 , respectively, and is comprised of current state taxes and foreign taxes withheld by governmental agencies outside of the United States, as follows (in thousands): Year Ended December 31, 2022 2021 Current: Federal $ — $ — State ( 13 ) ( 2 ) Foreign ( 1 ) — Total current tax (expense) ( 14 ) ( 2 ) Deferred: Federal — — State — — Foreign — — Total deferred tax (expense) — — Total tax (expense) $ ( 14 ) $ ( 2 ) The Company operates in only one federal jurisdiction, the United States. The following is a reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows: Year Ended December 31, 2022 2021 Expected income tax provision at the federal statutory rate 21.0 % 21.0 % State taxes, net of federal benefits 16.0 % ( 20.1 )% Impact of Section 382 Study — ( 10.4 )% Change in valuation allowance ( 40.9 )% ( 0.4 )% Transaction costs — ( 1.0 )% Derivative liability 4.1 % 11.7 % Contingent Consideration Release 0.1 % — Non-controlling interest ( 0.3 )% ( 1.9 )% Gain on debt extinguishment — 1.5 % Other ( 0.1 )% ( 0.4 )% Income tax provision ( 0.1 )% — Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, net operating loss carryforwards (“NOLs”) and other tax credits. Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands): As of December 31, 2022 2021 Deferred tax assets: Net operating loss carryforwards $ 19,654 $ 14,586 Unearned revenue — 1 Stock-based compensation 4,541 3,677 Accrued payroll and benefits 296 3 Research and development credits 16 16 Fixed asset basis difference 54 73 Inventory reserve 445 422 Charitable contributions 2 2 Income from partnerships 97 163 Lease liability 531 752 Contingent consideration — 456 Allowance for bad debt 65 27 Amortized intangibles 819 660 Goodwill 393 366 Section 174 Capitalization 340 — Total deferred tax assets 27,253 21,204 Deferred tax liabilities: Right of use asset ( 486 ) ( 699 ) Amortizable intangibles — — Income from partnerships — — Other — — Total deferred tax liabilities ( 486 ) ( 699 ) Less valuation allowance ( 26,767 ) ( 20,505 ) Net deferred tax assets $ — $ — Realization of the deferred tax assets is dependent upon future taxable income, if any, the amount and timing of which are uncertain. Accordingly, the net deferred tax assets have been offset by a valuation allowance. The net valuation allowance increased by $ 6.3 million during the year ended December 31, 2022 and decreased by $ 6,000 during the year ended December 31, 2021. At December 31, 2022 , the Company had federal and state NOLs aggregating approximately $ 81.1 million and $ 47.5 million, respectively. At December 31, 2022, the utilization of a portion of the federal NOLs is subject to an annual limitation under Section 382 of the Internal Revenue Code (IRC). Of the $ 222.3 million of federal NOLs available, approximately $ 141.2 million are expected to expire unutilized due to ownership changes as defined in IRC Section 382. If not utilized, the federal and state NOLs will begin to expire in 2023 and 2024, respectively. IRC Section 382 may also limit NOLs generated in future years. The Company evaluates deferred tax assets, including the benefit from NOLs, to determine if a valuation allowance is required. Such evaluation is based on consideration of all available evidence using a “more likely than not” standard with significant weight being given to evidence that can be objectively verified. This assessment considers, among other matters, the nature, frequency, and severity of current and cumulative losses; forecasts of future profitability; the length of statutory carryforward periods; the Company’s experience with operating losses; and tax-planning alternatives. The significant piece of objective negative evidence evaluated was the cumulative loss incurred through the year ended December 31, 2022 . Given this evidence and the expectation to incur operating losses in the foreseeable future, a full valuation allowance has been recorded against the net deferred tax asset. The Company will continue to maintain a full valuation allowance against the entire amount of its net deferred tax asset, until such time as the Company has determined that the weight of the objectively verifiable positive evidence exceeds that of the negative evidence and it is likely that the Company will be able to utilize all of its net deferred tax asset relating to its federal and state NOL carryforwards. Although the Company has established a full valuation allowance on its net deferred tax asset, for Federal tax losses before 2018 and for all state tax losses, it has not forfeited the right to carryforward tax losses up to 20 years and apply such tax losses against taxable income in such years, thereby reducing its future tax obligations. Federal tax losses generated in 2018 and later do not expire. The Company is subject to taxation in the United States and various state jurisdictions. As of December 31, 2022 , the Company’s tax years for 2003 through 2022 are generally subject to examination by the tax authorities. The years are open back to 2003 to the extent the NOLs being carried forward were generated then. As of December 31, 2022, the Company had the following unrecognized tax benefits (in thousands): Year Ended December 31, 2022 2021 Unrecognized tax benefit beginning balance $ 17 $ 17 Increases for tax positions taken in prior years — — Decreases for tax positions taken in prior years ( 1 ) — Increases for tax positions taken in current years — — Settlements — — Unrecognized tax benefit ending balance $ 16 $ 17 In February 2023, the Company received notification from the Internal Revenue Service that our Archipelago joint venture was selected for audit for the 2021 tax year. The Opening Conference is scheduled for April 24, 2023, and Management has not yet received the IRS agent’s Initial Document Request. The Company is currently not under audit for state purposes. The Company does not anticipate its total unrecognized tax benefits as of December 31, 2022 will significantly change due to settlement of examination or the expiration of statute of limitations during the next 12 months. The Company is currently unaware of any uncertain tax positions that could result in significant additional payments, accruals or other material deviation in this estimate over the next 12 months.

Retirement Benefits

Retirement Benefits	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
Retirement Benefits	Note 20. Retirement Benefits The Company has a 401(k) retirement plan (the “Plan”) available for participation by all regular full-time employees who have completed three months of service with the Company. The Company established the Plan in 2008. The Plan provides for a discretionary matching contribution equal to 50 % of the amount of the employee’s salary deduction, not to exceed 3 % of the salary per employee. Highly compensated employees are excluded from receiving any discretionary matching contribution. Employees’ rights to employer contributions vest on the one-year anniversary of their date of employment. The Company has the option to make discretionary matching contributions. The Company did no t make discretionary matching contributions during the years ended December 31, 2022 and 2021 .

Segment Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Segment and Geographic Information	Note 21. Segment and Geographic Information Management has determined that it has one business activity and operates in one segment as it only reports financial information on an aggregate and consolidated basis to its Chief Executive Officer, who is the Company’s chief operating decision maker. Revenues based on the location of the customers, are as follows (in thousands): Year Ended December 31, 2022 2021 United States $ 8,836 $ 6,003 Argentina 862 26 India 7 7 Canada 194 503 Spain — 225 United Kingdom — 16 Germany 57 — Total $ 9,956 $ 6,780

Net Loss per Share

Net Loss per Share	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Net Loss per Share	Note 22. Net Loss per Share Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period and excludes any dilutive effects of stock-based awards, warrants and options. Diluted net loss per share attributable to common stockholders is computed giving effect to all potentially dilutive common shares, including common stock issuable upon exercise of stock options and warrants. As the Company had net losses for the years ended December 31, 2022 and 2021, all potentially dilutive common shares were determined to be anti-dilutive. Securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows (in shares): Year Ended December 31, 2022 2021 Options to purchase common stock 60,002 35,554 Warrants to purchase common stock 285,757 287,750 Preferred investment options 123,967 — Total 469,726 323,304

Related-Party Transactions

Related-Party Transactions	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Related-Party Transactions	Note 23. Related Party Transactions The Company’s related parties include Moral Compass Corporation (“MCC”) and the John Sperling Foundation (“JSF”). The rights to the intellectual property owned by Blue Horse Labs, Inc. (“BHL”) were assigned to its sole shareholder, the John Sperling Revocable Trust (“JSRT”) due to BHL’s dissolution and then subsequently to the JSF. The JSF is deemed a related party of the Company because MCC, the Company’s largest stockholder, and the JSF share common officers and directors. Transactions with related parties are reflected in the consolidated financial statements under amounts due to related parties. Outlined below are details of agreements between the Company and its related parties: JSF receives a single digit royalty from the Company when revenue has been collected on product sales or for license payments from third parties that involve certain intellectual property developed under research funding originally from BHL. Royalty fees due to JSF were $ 48,000 and $ 64,000 as of December 31, 2022 and December 31, 2021, respectively, and are included in the consolidated balance sheets as amounts due to related parties. During the year ended December 31, 2021, the Company leased land on the island of Molokai, Hawaii from an entity owned by Kevin Comcowich, the Chair of the Company’s Board of Directors, and his wife. The Company used to grow hemp on this land to support the operations of its joint venture Archipelago Ventures Hawaii, until the expiration of the lease in February 2022. The original lease was executed in February 2019, covers 10 acres of land, has a term of two years and provides for rent payments of $ 1,200 per acre per year. In March and April 2020, the Company entered into two lease amendments for two additional 10 -acre parcels and two additional 15 -acre parcels , at the same lease rate of $ 1,200 per acre per year, and with a term of two years . The Company made lease payments in the amount of $ 0 and $ 84,000 during the years ended December 31, 2022 and 2021, respectively. Mr. Comcowich served as the Company's interim chief executive officer from January 1, 2022 to February 1, 2022, and received $ 34,000 in total compensation for his services in this role. During the year ended December 31, 2022, the Company sold Archipelago equipment to Mr. Comcowich at fair value. The impact of the transaction on the consolidated financial statements was not material.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 24. Subsequent Events On March 2, 2023, the Company entered into a securities purchase agreement pursuant to which it sold in a private placement (i) 165,500 shares of common stock (“March 2023 PIPE Shares”), (ii) pre-funded common stock purchase warrants (“March 2023 Pre-Funded Warrants”) to purchase up to 500,834 shares of common stock, at an exercise price of $ 0.0001 per share, and (iii) preferred investment options (“March 2023 Options”) to purchase up to 1,332,668 shares of common stock, at an exercise price of $ 9.00 per share, for gross proceeds of $ 6.0 million (the “March 2023 PIPE”). The March 2023 PIPE closed on March 6, 2023 . At the closing of the March 2023 PIPE, the Company also reduced the exercise price of outstanding warrants to purchase a total of 178,132 shares of common stock that were previously issued to the investors in the March 2023 PIPE. The March 2023 Pre-Funded Warrants became exercisable upon issuance and are exercisable until exercised in full. The March 2023 Options became exercisable upon issuance with 666,334 options expiring 18 months after the date of issuance and the remaining 666,334 options expiring 5 years after the date of issuance. The Company agreed to register the resale of the March 2023 PIPE Shares and the shares issuable upon exercise of the March 2023 Pre-Funded Warrants and March 2023 Options. In connection with the March 2023 PIPE, the Company granted to a placement agent preferred investment options ("March 2023 Placement Agent Options") to purchase a total of 33,317 shares of common stock that have an exercise price per share equal to $ 11.25 and a term of five years .

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Organization	Organization Arcadia Biosciences, Inc. (the "Company," "Arcadia" or "management"), was incorporated in Arizona in 2002 and maintains its headquarters in Dallas, Texas, with additional office space in Davis, California, and additional facilities in American Falls, Idaho. The Company was reincorporated in Delaware in March 2015 . The Company is a producer and marketer of innovative, plant-based food and beverage products. Its history as a leader in science-based approaches to developing high-value crop improvements, as well as nutritionally enhanced food ingredients, has laid the foundation for its path forward. The Company used advanced breeding techniques to develop these proprietary innovations which are now being commercialized through the sales of seed and grain, as well as food ingredients and products. The acquisition of the assets of Live Zola, LLC (“Zola”) added coconut water to the Company's portfolio of products. In May 2021, the Company’s wholly owned subsidiary Arcadia Wellness, LLC (“Arcadia Wellness” or “AW”, see Note 7), acquired the businesses of Eko, Lief, and Zola. The acquisition included consumer CBD brands like Soul Spring™, a CBD-infused botanical therapy brand in the natural category, Saavy Naturals™, a line of natural body care products and ProVault™, a CBD-infused sports performance formula made with natural ingredients, providing effective support and recovery for athletes. Also included in the purchase was Zola, a coconut water sourced exclusively with sustainably grown coconuts from Thailand. On July 8, 2022, the Company entered into an agreement to license Saavy Naturals™ to Radiance Beauty and Wellness, Inc. ("Radiance Beauty"). See Note 7 for a discussion of the licensing agreement. In April 2021, the newly formed Company’s wholly owned subsidiary Arcadia SPA, S.L. (“Arcadia Spain” or “ASPA”) acquired the physical and intellectual property assets of Agrasys S.A. (“Agrasys”), a food ingredients company based in Barcelona, Spain. The Company sold all of the assets and liabilities related to the subsidiary Arcadia Spain in November 2021 to a European buyer (the "buyer"), to focus on the US domestic market. The loss on sale of Arcadia Spain recorded on the consolidated statements of operations and comprehensive loss was $ 497,000 . The buyer assumed all present and future liabilities, including the initial commitments related to the 2022 planting season. In August 2019, the Company entered into a joint venture agreement with Legacy Ventures Hawaii, LLC (“Legacy,” see Note 9) to grow, extract, and sell hemp products. The partnership Archipelago Ventures Hawaii, LLC (“Archipelago”), combines the Company’s extensive genetic expertise and resources with Legacy’s experience in hemp extraction and sales. In October 2021, Arcadia and Legacy mutually agreed to wind down the cultivation activities of Archipelago, due to regulatory challenges and a saturated hemp market. As a result, the Company recorded impairments of property and equipment in the amount of $ 160,000 and $ 1.4 million for the years ended December 31, 2022, and 2021, respectively. The Company assessed Archipelago’s fixed assets for impairment through an asset recoverability test, using prices for similar assets. See Note 5.
Reverse Stock Split	Reverse Stock Split In February 2023, the Company’s board of directors approved a reverse split of 40:1 on the Company’s issued and outstanding common stock. On February 15, 2023, the Company’s stockholders approved the certificate of amendment, which the Company filed on February 27, 2023 with the Secretary of State of Delaware to effect the reverse split on March 1, 2023. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the consolidated financial statement have been retroactively adjusted to reflect the reverse stock split for all periods presented
Liquidity, Capital Resources, and Going Concern	Liquidity, Capital Resources, and Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. Since inception, the Company has financed its operations primarily through equity and debt financings. As of December 31, 2022, the Company had an accumulated deficit of $ 257.9 million, and cash and cash equivalents of $ 20.6 million. For the years ended December 31, 2022 and 2021, the Company had net losses of $ 15.6 million and $ 16.1 million, respectively, and net cash used in operations of $ 14.0 million and $ 25.9 million, respectively. The Company believes that its existing cash and cash equivalents will not be sufficient to meet its anticipated cash requirements for at least the next 12-18 months from the issuance date of these financial statements, and thus raises substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company may seek to raise additional funds through debt or equity financings. The Company may also consider entering into additional partner arrangements. The sale of additional equity would result in dilution to the Company’s stockholders. The incurrence of debt would result in debt service obligations, and the instruments governing such debt could provide for additional operating and financing covenants that would restrict operations. If the Company does require additional funds and is unable to secure adequate additional funding at terms agreeable to the Company, the Company may be forced to reduce spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned development programs. Any of these actions could materially harm the business, results of operations and financial condition.
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The consolidated financial statements include the accounts of the Company, Arcadia Wellness and Archipelago. All intercompany balances and transactions have been eliminated in consolidation. The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP (“GAAP”), and with the rules of the Securities and Exchange Commission. The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities ("VIEs"). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIE’s economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE. For all periods presented, the Company has determined that it is the primary beneficiary of Archipelago, a joint venture, as it has a controlling interest in Archipelago. Accordingly, the Company consolidates Archipelago in the consolidated financial statements after eliminating intercompany transactions. For consolidated joint ventures, the non-controlling partner’s share of the assets, liabilities and operations of the joint venture is included in non-controlling interests as equity of the Company. The non-controlling partner’s interest is generally computed as the joint venture partner’s ownership percentage of Archipelago. Net loss attributable to non-controlling interest of $ 236,000 and $ 1.5 million is recorded as an adjustment to net loss to arrive at net loss attributable to common stockholders for the years ended December 31, 2022 and 2021, respectively. The non-controlling partner’s equity interests are presented as non-controlling interests on the consolidated balance sheets as of December 31, 2022 and 2021. The functional currency of the foreign subsidiary Arcadia Spain during the year ended December 31, 2021, was its local currency (i.e., the Euro). Accordingly, period-end exchange rates were applied to translate its assets and liabilities and average transaction exchange rates to translate its revenues, expenses, gains, and losses into U.S. dollars. Upon disposal of all of the assets and liabilities related to Arcadia Spain, the Company deconsolidated the accounts of the subsidiary as of November 30, 2021, and recorded a loss on the sale in the amount of $ 497,000 during the year ended December 31, 2021.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions in the Company’s consolidated financial statements and notes thereto. Significant estimates and assumptions made by management included the determination of the provision for income taxes, stock-based compensation, impairments of long-lived assets such as intangible assets and goodwill, impairment of property and equipment, net realizable value of inventory, and contingent liabilities. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.
Cash and cash equivalents	Cash and cash equivalents The Company considers any liquid investment with a stated maturity of three months or less at the date of purchase to be a cash equivalent. Cash and cash equivalents consist of cash on deposit with banks and money-market funds. The Company limits cash investments to financial institutions with high credit standings; therefore, management believes that there is no significant exposure to any credit risk in the Company’s cash and cash equivalents. However, as of December 31, 2022 and 2021, a portion of the Company’s cash in depository accounts is in excess of the federal deposit insurance limits.
Investments in debt and equity securities	Investments in debt and equity securities Investments in debt and equity securities are carried at fair value and classified as short-term investments. Realized and unrealized gains and losses on investment securities are included in other income, net, in the consolidated statements of operations and comprehensive loss. Investment securities are reported as cash and cash equivalent, short-term investments or long-term investments in the consolidated balance sheets based on the nature of the investments and maturity period. Short-term investments have maturities of less than a year and long-term investments have maturities of a year and greater from the balance sheet date.
Other-than-temporary impairments on investments	Other-than-temporary impairments on investments The Company regularly reviews each of its investments for impairment by determining if the investment has sustained an other-than-temporary decline in its value, in which case the investment is written down to its fair value by a charge to earnings. Factors that are considered by the Company in determining whether an other-than-temporary decline in value has occurred include (i) the market value of the investment in relation to its cost basis, (ii) the financial condition of the investment, and (iii) the Company’s intent and ability to retain the investment for a sufficient period of time to allow for recovery of the market value of the investment. As of December 31, 2022 and 2021, there was no impairment of the Company’s investments.
Accounts receivable and other receivables	Accounts receivable and other receivables Accounts receivable represents amounts owed to the Company from product sales, licenses, and royalties. Other receivables represent amounts owed to the Company for miscellaneous non-trade activities including the sale of property and equipment. The carrying value of the Company’s receivables represents estimated net realizable values. The Company generally does not require collateral and estimates any required allowance for doubtful accounts based on historical collection trends, the age of outstanding receivables, and existing economic conditions. If events or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectability of those balances and the allowance is recorded accordingly. Past-due receivable balances are written off when the Company’s internal collection efforts have been unsuccessful in collecting the amounts due. The Company had $ 3,000 and $ 76,000 amounts reserved for doubtful accounts at December 31, 2022 and 2021, respectively, and the allowance activity during the year ended December 31, 2022, was immaterial.
Inventory	Inventory Inventory costs are tracked on a lot-identified basis and are included as cost of revenues when sold. Inventories are stated at the lower of cost or net realizable value. The Company makes adjustments to inventory when conditions indicate that the net realizable value may be less than cost due to physical deterioration, obsolescence, changes in price levels, or other factors. Additional adjustments to inventory are made for excess and slow-moving inventory on hand that is not expected to be sold within a reasonable timeframe to reduce the carrying amount to its estimated net realizable value . GoodWheat: Proprietary wheat plants are grown, producing seed and grain with a variety of improved nutritional qualities, including high levels of amylose, improved shelf life, and reduced gluten. The seed is used for subsequent plantings and the grain is either sold or used as an ingredient in the production of food products, which the Company refers to collectively as GoodWheat products. Amounts inventoried consist primarily of fees paid to contracted cooperators to grow the crops, costs to process harvested seed and grain, and costs to mill the grain into flour. Body care : A portfolio of CBD-infused and CBD-free consumer bath and body care products such as body lotions, bath-bombs and topical pain relievers, that are produced in the US. Amounts inventoried consist primarily of purchased raw materials, components, labor, and manufacturing facility costs. Zola Coconut water : Inventories mainly consist of coconut water imported from Thailand, freight-in, supplies, and labor. GoodHemp : Proprietary seeds are grown and used for subsequent plantings and sold as final product to other growers. Amounts in inventory for internally produced hemp seeds consist primarily of labor, supplies and facility costs. The costs to procure seeds from external growers and suppliers are included in inventory, as well. In addition, hemp seeds were planted on land leased in Hawaii. The costs of purchasing, planting and growing the seed, and harvesting the resulting biomass are captured as inventory, along with the costs to process the biomass into CBD oil. Amounts in inventory for growing biomass primarily consist of labor, supplies and facility costs. The inventories—current line item on the balance sheet represents inventory forecasted to be sold or used in production in the next 12 months, as of the balance sheet date, and consists primarily of the cost of GoodWheat grain, Zola Coconut water, and GoodHemp seeds. The inventories—noncurrent line item on the balance sheet represents inventory expected to be used in production or sold beyond the next 12 months, as of the balance sheet date, and consists primarily of GoodWheat seed and grain. Raw materials inventories consist primarily of GoodWheat seeds and in-transit Zola Coconut Water. Finished goods inventories consist primarily of GoodWheat grain, Zola Coconut Water, and GoodHemp seeds that are available for sale.
Property and equipment	Property and equipment Property and equipment acquisitions are recorded at cost. Provisions for depreciation are calculated using the straight-line method over the following average estimated useful lives of the assets: Years Laboratory equipment 5 Software and computer equipment 3 Machinery and equipment 2 - 20 Furniture and fixtures 7 Vehicles 5 Leasehold improvements 2 - 10 * *Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the remaining life of the lease.
Impairment of long-lived intangible assets and goodwill	Impairment of long-lived intangible assets and goodwill The Company evaluates if events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and identifiable intangible assets may warrant revision or that the remaining balance of these assets may not be recoverable. In evaluating for recoverability, the Company estimates the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. In the event that the balance of any asset exceeds the future undiscounted cash flow estimate, impairment is recognized based on the excess of the carrying amounts of the asset above its estimated fair value. Intangible assets, net During the years ended December 31, 2022 and 2021, there were $ 404,000 and $ 3.3 million, respectively of impairm ent of intangible assets, recorded on the consolidated statements of operations and comprehensive loss. See Note 8 for more information. Goodwill No goodwill impairment charges were recorded during the year ended December 31, 2022. During the year ended December 31, 2021, the Company recorded an impairment charge of $ 1.6 million, which was included as impairment of goodwill on our consolidated statements of operations and comprehensive loss. The impairment charge was primarily the result of weakness in our newly acquired consumer product margins combined with a volatile economic climate and higher than normal inflation. The decline in the stock price observed during the fourth quarter of 2021, pushed our market capitalization significantly below the recorded value of our stockholders' equity.
Fair value of financial instruments	Fair value of financial instruments Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. Assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities, are as follows: • Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date. • Level 2 inputs are observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 inputs are unobservable inputs for the asset or liability. The carrying values of the Company’s financial instruments, including cash equivalents, accounts receivable, and accounts payable approximated their fair values due to the short period of time to maturity or repayment.
Concentration of risk	Concentration of risk Cash and cash equivalents are maintained with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate its credit risks by spreading such risks across multiple counterparties and monitoring the risk profiles of these counterparties.
Customer concentration	Customer concentration Significant customers are those that represent greater than 10% of the Company’s total revenues or gross accounts receivable balance at each respective balance sheet date. Customers representing greater than 10% of accounts receivable were as follows (in percentages): As of 2022 2021 Customer B — 11 Customer D — 15 Customer E — 11 Customer A 57 — Customers representing greater than 10% of total revenues were as follows (in percentages): For Year Ended 2022 2021 Customer D — 11 Customer B — 10 Customer F 13 —
Stock-based compensation	Stock-based compensation The Company recognizes compensation expense related to its employee stock purchase plan and the cost of stock-based compensation awards on a straight-line basis over the requisite service period, net of estimated forfeitures. Judgment is required in estimating the amount of stock-based awards that will be forfeited prior to vesting. Compensation expense could be revised in subsequent periods if actual forfeitures differ from those estimates. The Company has selected the Black-Scholes option-pricing model and various inputs to estimate the fair value of its stock-based awards. See Note 15 for additional information. Amounts recognized in the consolidated statements of operations and comprehensive loss were as follows (in thousands): Year Ended December 31, 2022 2021 Research and development $ 75 $ 98 Selling, general and administrative 1,031 1,443 Total stock-based compensation $ 1,106 $ 1,541
Income taxes	Income taxes The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.
Net loss per share	Net loss per share Basic net loss per share, which excludes dilution, is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock, such as stock options, convertible promissory notes, convertible preferred stock, redeemable convertible preferred stock and warrants, result in the issuance of common stock which share in the losses of the Company. Certain potential shares of common stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. Such potentially dilutive shares are excluded when the effect would be to reduce the loss per share. Due to net losses, there is no impact on earnings per share calculation in applying the two-class method since the participating securities have no legal requirement to share in any losses.
Revenue recognition	Revenue recognition The Company derives its revenues from product sales, licensing agreements and royalty fees.
Unearned revenue	Unearned revenue The Company defers revenue to the extent that cash received in conjunction with a license agreement is not yet earned in accordance with the Company policies.
Cost of product revenues	Cost of revenues Cost of revenues relates to the sale of Arcadia Wellness, GoodWheat, and GLA products and consists of the cost of raw materials, including internal and third-party services costs related to procuring, processing, formulating, packaging and shipping our products, as well as in-licensing and royalty fees, any adjustments or write-downs to inventory or prepaid production costs.
Research and development expenses	Research and development expenses Research and development expenses consist of costs incurred in the development and testing of the Company's products and other products in development incorporating the Company's traits. These expenses currently consist primarily of fees paid to product formulation consultants and are expensed as incurred. Additionally, the Company is required from time to time to make certain milestone payments in connection with the development of technologies in-licensed from third parties. The Company's research and development expenses may fluctuate from period to period.
Change in fair value of contingent consideration	Change in fair value of contingent consideration Change in the fair value of contingent consideration is comprised of the gain associated with the reduction of the contingent liability. See Note 6 and Note 16.
Change in the estimated fair value of common stock warrant and option liabilities	Change in the estimated fair value of common stock warrant and option liabilities Change in the estimated fair value of common stock warrant and option liabilities is comprised of the fair value remeasurement of liability classified common stock warrants and options. See Note 14.
Product Revenues
Revenue recognition	Product revenues Product revenues consist primarily of sales of Arcadia Wellness products, GoodWheat grain and pasta, and GLA products. We recognize revenue from product sales when control of the product is transferred to third-party distributors and manufacturers, collectively “our customers,” which generally occurs upon delivery. The Company's revenues fluctuate depending on the timing of shipments of product to our customers and are reported net of estimated chargebacks, returns and losses.
License Revenues
Revenue recognition	License revenues License revenues to date consist of up-front, nonrefundable license fees, annual license fees, and subsequent milestone payments that the Company receives under the Company’s research and license agreements. The Company recognizes revenue generated from up-front, nonrefundable license fees upon execution of the agreement and recognizes annual license fees when it is probable that a material reversal will not occur. Milestone fees are variable consideration that is initially constrained and recognized only when it is probable that such amounts would not be reversed. The Company assesses when achievement of milestones is probable to determine the timing of revenue recognition for milestone fees. Milestones typically consist of significant stages of development for the Company’s traits in a potential commercial product, such as achievement of specific technological targets, completion of field trials, filing with regulatory agencies, completion of the regulatory process, and commercial launch of a product containing the Company’s traits. Given the seasonality of agriculture and time required to progress from one milestone to the next, achievement of milestones is inherently uneven, and the Company’s license revenues are likely to fluctuate significantly from period to period.
Royalty
Revenue recognition	Royalty revenues Royalty revenues consist of amounts earned from the sale of commercial products that incorporate the Company's traits by third parties. Royalty revenues consist of a minimum annual royalty, offset by amounts earned from the sale of products. The Company recognizes the minimum annual royalty on a straight-line basis over the year, and the Company recognizes royalty revenue resulting from the sale of products when the third parties transfer control of the product to their customers, which generally occurs upon shipment. Royalty revenues can fluctuate depending on the timing of shipments of product by the third parties to their customers.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Average Estimated Useful Lives of Assets	Provisions for depreciation are calculated using the straight-line method over the following average estimated useful lives of the assets: Years Laboratory equipment 5 Software and computer equipment 3 Machinery and equipment 2 - 20 Furniture and fixtures 7 Vehicles 5 Leasehold improvements 2 - 10 * *Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the remaining life of the lease.
Amounts Recognized in Consolidated Statements of Operations and Comprehensive Loss Net	Amounts recognized in the consolidated statements of operations and comprehensive loss were as follows (in thousands): Year Ended December 31, 2022 2021 Research and development $ 75 $ 98 Selling, general and administrative 1,031 1,443 Total stock-based compensation $ 1,106 $ 1,541
Schedule of Customers Representing Greater than 10% of Account Receivable and Total Revenue	Significant customers are those that represent greater than 10% of the Company’s total revenues or gross accounts receivable balance at each respective balance sheet date. Customers representing greater than 10% of accounts receivable were as follows (in percentages): As of 2022 2021 Customer B — 11 Customer D — 15 Customer E — 11 Customer A 57 — Customers representing greater than 10% of total revenues were as follows (in percentages): For Year Ended 2022 2021 Customer D — 11 Customer B — 10 Customer F 13 —

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Summary of Inventories	Inventories, net consist of the following (in thousands): December 31, December 31, Raw materials $ 610 $ 1,851 Goods in process — 842 Finished goods 2,728 4,234 Inventories $ 3,338 $ 6,927

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment, Net	Property and equipment, net consisted of the following (in thousands): As of December 31, 2022 2021 Laboratory equipment $ 679 $ 2,659 Software and computer equipment 407 548 Machinery and equipment 450 1,809 Furniture and fixtures 83 211 Vehicles 306 417 Leasehold improvements 1,590 2,306 Property and equipment, gross 3,515 7,950 Less accumulated depreciation and amortization ( 2,811 ) ( 5,659 ) Property and equipment, net $ 704 $ 2,291

Investments and Fair Value In_2

Investments and Fair Value Instruments (Tables)	12 Months Ended
	Dec. 31, 2022
Investments And Fair Value Instruments [Abstract]
Summary of Amortized Cost and Fair Value of Investment Securities Portfolio	(Dollars in thousands) Amortized Unrealized Unrealized Estimated December 31, 2022 Cash equivalents: Money market funds $ 18,620 $ — $ — $ 18,620 Total Assets at Fair Value $ 18,620 $ — $ — $ 18,620 (Dollars in thousands) Amortized Unrealized Unrealized Estimated December 31, 2021 Cash equivalents: Money market funds $ 26,842 $ — $ — $ 26,842 Total Assets at Fair Value $ 26,842 $ — $ — $ 26,842
Summary of Fair Value of Investment Securities	The fair value of the investment securities at December 31, 2022 were as follows: Fair Value Measurements at December 31, 2022 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 18,620 $ — $ — $ 18,620 Total Assets at Fair Value $ 18,620 $ — $ — $ 18,620 The fair value of the investment securities at December 31, 2021 were as follows: Fair Value Measurements at December 31, 2021 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 26,842 $ — $ — $ 26,842 Total Assets at Fair Value $ 26,842 $ — $ — $ 26,842
Summary of Preferred Investment Option Liabilities Measured and Recorded on Recurring Basis using Black-Scholes Model	The preferred investment option liabilities were measured and recorded on a recurring basis using the Black-Scholes Model with the following assumptions at December 31, 2022: August 2022 Options August 2022 Placement Agent Options December 31, December 31, Expected term (in years) 4.67 4.67 Expected volatility 106.2 % 106.2 % Risk-free interest rate 4.0 % 4.0 % Expected dividend yield 0 % 0 %
Summary of Changes in Fair Value and Other Adjustments of Liabilities	The following table sets forth the establishment of the Company’s Level 3 liabilities, as well as a summary of the changes in the fair value and other adjustments (in thousands): (Dollars in thousands) Common Stock Common Common Common August 2022 August 2022 Contingent Total Balance as of December 31, 2021 $ 7 $ 170 $ 223 $ 2,993 $ — $ — $ 2,070 $ 5,463 Reclassification upon adoption ( 7 ) ( 170 ) ( 223 ) ( 2,993 ) — — — ( 3,393 ) Initial recognition — — — — 3,824 191 — 4,015 Change in fair value and — — — — ( 3,057 ) ( 152 ) ( 70 ) ( 3,279 ) Balance as of December 31, 2022 $ — $ — $ — $ — $ 767 $ 39 $ 2,000 $ 2,806

Industrial Seed Innovations Acq

Industrial Seed Innovations Acquisition (Tables)	12 Months Ended
	Dec. 31, 2022
Business Combinations [Abstract]
Schedule of Allocation Purchase Price of Assets Acquired at Fair Value at Acquisition Date	The following table presents the allocation of the purchase price of the assets acquired, based on their fair values at the acquisition date (in thousands): Purchase Price Inventory $ 840 Prepaid and other current assets 62 Fixed assets 308 Deposits 82 Customer list 360 Trade names and trademarks 2,900 Formulations 260 Goodwill 1,240 Total consideration allocated $ 6,052

Arcadia Wellness Acquisition (T

Arcadia Wellness Acquisition (Tables)	12 Months Ended
	Dec. 31, 2022
Business Combinations [Abstract]
Schedule of Allocation Purchase Price of Assets Acquired at Fair Value at Acquisition Date	The following table presents the allocation of the purchase price of the assets acquired, based on their fair values at the acquisition date (in thousands): Purchase Price Inventory $ 840 Prepaid and other current assets 62 Fixed assets 308 Deposits 82 Customer list 360 Trade names and trademarks 2,900 Formulations 260 Goodwill 1,240 Total consideration allocated $ 6,052
Schedule of Unaudited Pro-forma Condensed Consolidated Results of Operations	The following unaudited pro-forma consolidated results of operations for the years ended December 31, 2022 and 2021, have been prepared as if the acquisition of Arcadia Wellness had occurred on January 1, 2021 and includes adjustments for amortization of intangibles, and the addition to basic and diluted weighted average number of shares outstanding. For the year 2022 2021 Total revenues $ 9,956 $ 9,062 Net loss ( 15,605 ) ( 17,854 ) Net loss attributable to common stockholders $ ( 15,376 ) $ ( 16,380 ) Weighted average shares - Basic and diluted 599,389 539,773 Net loss per share attributable to common stockholders: Basic and diluted $ ( 25.65 ) $ ( 30.35 )

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets, Net	The Company’s intangible assets, net as of December 31, 2022 and 2021, consist of the following (in thousands): December 31, 2022 December 31, 2021 Gross Accumulated Amortization Net Carrying Gross Accumulated Amortization Net Carrying Amortized intangible assets Intellectual property $ 144 $ 141 $ 3 $ 570 $ 419 $ 151 Customer lists 33 31 2 400 355 45 Total amortizable intangible assets $ 177 $ 172 $ 5 $ 970 $ 774 $ 196 Indefinite-lived intangible assets Brands and trademarks $ 35 $ — $ 35 $ 2,950 $ 2,662 $ 288 Total intangible asset, net $ 212 $ 172 $ 40 $ 3,920 $ 3,436 $ 484 (1) During the years ended December 31, 2022 and 2021, the Company estimated an overall decrease in the sales forecast for AW products, due to an inventory item rationalization, in addition to a decrease in the sales forecast of ISI seeds, related to the saturated hemp seed market. As a result, Arcadia performed a quantitative intangible assets impairment test. The Company used a discounted cash flow approach to develop the fair value of our acquired intellectual property, customer lists, brands and trademarks. As a result of this assessment, Arcadia recorded an impairment of intangible assets in the amount of $ 404,000 and $ 3.3 million in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2022 and 2021, respectively. Of the impairment recognized during the year ended December 31, 2022, $ 72,000 was related to the Radiance Beauty licensing agreement.

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Summary of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses consisted of the following (in thousands): As of December 31, 2022 2021 Accounts payable - trade $ 931 $ 1,411 Payroll and benefits 1,373 1,606 Inventory 69 72 Royalty fees due to unrelated parties 6 51 Consulting 8 79 Rent and utilities 28 127 Audit and tax fees 99 72 Legal 69 58 Other 298 162 Total accounts payable and accrued expenses $ 2,881 $ 3,638

Warrants and Options (Tables)

Warrants and Options (Tables)	12 Months Ended
	Dec. 31, 2022
Warrants and Rights Note Disclosure [Abstract]
Summary of Warrants Issued to Purchase Common Stock	The Company issued the following warrants to purchase shares of its common stock, which are outstanding as of December 31, 2022 and 2021, respectively. These warrants are exercisable any time at the option of the holder until their expiration date. Issuance Date Term Exercise Warrants Warrants Warrants Warrants December 2022 Service and Performance Warrants (1) December 2022 5 years $ 11.20 — — — 1,000 October 2022 Service and Performance Warrants (1) October 2022 5 years $ 16.00 — — — 1,000 August 2022 Pre-Funded Warrants August 2022 perpetual $ — — — — 56,813 January 2021 Placement Agent Warrants January 2021 5.5 years $ 159.60 — 9,846 — 9,846 January 2021 Service and Performance Warrants (1) January 2021 2 years $ 123.20 — 188 — 188 December 2020 Warrants December 2020 5.5 years $ 120.00 — 65,467 — 65,467 December 2020 Placement Agent Warrants December 2020 5 years $ 152.80 — 3,274 — 3,274 July 2020 Warrants July 2020 5.5 years $ 154.00 — 16,036 — 16,036 July 2020 Placement Agent Warrants July 2020 5.5 years $ 198.80 — 802 — 802 May 2020 Warrants May 2020 5 years $ 191.20 — 34,809 — 34,809 May 2020 Placement Agent Warrants May 2020 5 years $ 245.20 — 1,741 — 1,741 March 2020 Service and Performance Warrants (1) March 2020 3 years $ 100.00 — 459 — 459 February 12, 2020 Service and Performance Warrants (1)(3) February 2020 2 years $ 188.40 — 3,750 — — February 3, 2020 Service and Performance Warrants (1)(3) February 2020 2 years $ 196.40 — 250 — — September 2019 Placement Agent Warrants September 2019 5 years $ 379.20 — 1,649 — 1,649 June 2019 Placement Agent Warrants June 2019 5 years $ 251.60 — 1,862 — 1,862 April 2019 Service and Performance Warrants (1) April 2019 5 years $ 247.20 — 3,629 — 3,629 June 2018 Placement Agent Warrants June 2018 5 years $ 502.80 — 1,741 — 1,741 March 2018 Placement Agent Warrants March 2018 5 years $ 1,662.40 — 376 — 376 January 2021 Warrants (2) January 2021 5.5 years $ 125.20 — 98,460 — 98,460 September 2019 Warrants (2) September 2019 5.5 years $ 300.80 — 16,486 — 16,486 June 2019 Warrants (2) June 2019 5.5 years $ 200.00 — 10,896 — 10,896 June 2018 Warrants (2) June 2018 5.5 years $ 397.60 — — — — March 2018 Warrants (2) March 2018 5 years $ 429.20 — 16,036 — 16,036 Total — 287,757 — 342,570 (1) The Company issued service and performance warrants (“Service and Performance Warrants”) in connection with professional services agreements with non-affiliated third party entities. (2) Certain warrants contain a contingent cash payment feature and therefore were accounted for as a liability at the date of issuance and were adjusted to fair value at each balance sheet date. Upon adoption of ASU No. 2020-06 on January 1, 2022, all of the common stock warrant liabilities have been reclassified to equity classified common stock warrants, due to the elimination of the contingent cash payments as criteria for liability classification. (3) These warrants expired in February 2022 .
Summary of Key Terms and Activity of Liability Classified Preferred Investment Options	The key terms and activity of the liability classified preferred investment options are summarized as follows: Issuance Date Term Exercise Exercised Outstanding at Exercised Outstanding at August 2022 Options August 2022 5 years $ 37.20 — — — 118,063 August 2022 Placement Agent Options August 2022 5 years $ 52.80 — — — 5,904 Total — — — 123,967

Stock-Based Compensation and _2

Stock-Based Compensation and Employee Stock Purchase Program (Tables)	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Summary of Activity Under Stock Incentive Plans	The following is a summary of stock option information and weighted average exercise prices under the Company’s stock incentive plans (in thousands, except share data and price per share): Shares Weighted- Aggregate Outstanding — Balance at December 31, 2020 22,243 $ 578.40 $ 9,600 Options granted 30,676 110.40 — Options exercised — — — Options forfeited ( 11,004 ) 123.60 43,440 Options expired ( 6,361 ) 1,160.80 — Outstanding — Balance at December 31, 2021 35,554 211.20 — Options granted 33,408 44.00 11,880 Options exercised — — — Options forfeited ( 6,658 ) 91.60 — Options expired ( 2,302 ) 644.80 — Outstanding — Balance at December 31, 2022 60,002 114.80 — Vested and expected to vest — December 31, 2022 54,018 121.60 — Exercisable —December 31, 2022 22,456 $ 215.20 $ —
Weighted-Average Fair Value Assumption of Stock Option Awards	The fair value of stock option awards was estimated at the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumption: Year Ended December 31, Assumptions 2022 2021 Expected term (years) 6.40 6.31 Expected volatility 122 % 121 % Risk-free interest rate 2.61 % 0.86 % Expected dividend yield — —

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Lessee Disclosure [Abstract]
Schedule of Leases	The Company’s lease agreements do not contain any material variable lease payments, material residual value guarantees or material restrictive covenants. Leases consisted of the following (in thousands): Leases Classification December 31, 2022 December 31, 2021 Assets Operating lease assets Right of use asset $ 1,848 $ 3,081 Total leased assets $ 1,848 $ 3,081 Liabilities Current - Operating Operating lease liability - current $ 1,010 $ 1,074 Noncurrent - Operating Operating lease liability - noncurrent 1,007 2,220 Total leased liabilities $ 2,017 $ 3,294 Lease Cost Classification For the For the Operating lease cost SG&A and R&D Expenses $ 1,028 $ 1,352 Short term lease cost (1) SG&A and R&D Expenses 6 133 Sublease income (2) SG&A and R&D Expenses ( 384 ) ( 63 ) Net lease cost $ 650 $ 1,422 (1) Sh ort term lease cost consists of field trial lease agreements with a lease term of 12 months or less. (2) Sublease income is recorded as a reduction to lease expense. Lease Term and Discount Rate December 31, 2022 December 31, 2021 Weighted-average remaining 2.4 2.7 Weighted-average discount rate 6 % 6 %
Schedule of Maturities of Operating Lease Liabilities	The maturities of the operating lease liabilities as of December 31, 2022 are as follows (in thousands): Years Ending December 31, Amounts 2023 $ 1,104 2024 886 2025 156 2026 and thereafter — Total operating lease payments $ 2,146 Less: imputed interest 129 Total current and noncurrent operating lease liabilities $ 2,017

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Components of Loss Before Income Taxes	The components of loss before income taxes are as follows (in thousands): Year Ended December 31, 2022 2021 Domestic $ ( 15,598 ) $ ( 16,006 ) Foreign — ( 126 ) Loss before income taxes $ ( 15,598 ) $ ( 16,132 )
Schedule of Income Tax Expense Comprised of Current State Taxes and Foreign Taxes	The total income tax expense for the years ended December 31, 2022 and 2021 was $ 14,000 and $ 2,000 , respectively, and is comprised of current state taxes and foreign taxes withheld by governmental agencies outside of the United States, as follows (in thousands): Year Ended December 31, 2022 2021 Current: Federal $ — $ — State ( 13 ) ( 2 ) Foreign ( 1 ) — Total current tax (expense) ( 14 ) ( 2 ) Deferred: Federal — — State — — Foreign — — Total deferred tax (expense) — — Total tax (expense) $ ( 14 ) $ ( 2 )
Reconciliation of the Statutory Federal Income Tax Rate	The following is a reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows: Year Ended December 31, 2022 2021 Expected income tax provision at the federal statutory rate 21.0 % 21.0 % State taxes, net of federal benefits 16.0 % ( 20.1 )% Impact of Section 382 Study — ( 10.4 )% Change in valuation allowance ( 40.9 )% ( 0.4 )% Transaction costs — ( 1.0 )% Derivative liability 4.1 % 11.7 % Contingent Consideration Release 0.1 % — Non-controlling interest ( 0.3 )% ( 1.9 )% Gain on debt extinguishment — 1.5 % Other ( 0.1 )% ( 0.4 )% Income tax provision ( 0.1 )% —
Deferred Tax Assets and Liabilities	Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands): As of December 31, 2022 2021 Deferred tax assets: Net operating loss carryforwards $ 19,654 $ 14,586 Unearned revenue — 1 Stock-based compensation 4,541 3,677 Accrued payroll and benefits 296 3 Research and development credits 16 16 Fixed asset basis difference 54 73 Inventory reserve 445 422 Charitable contributions 2 2 Income from partnerships 97 163 Lease liability 531 752 Contingent consideration — 456 Allowance for bad debt 65 27 Amortized intangibles 819 660 Goodwill 393 366 Section 174 Capitalization 340 — Total deferred tax assets 27,253 21,204 Deferred tax liabilities: Right of use asset ( 486 ) ( 699 ) Amortizable intangibles — — Income from partnerships — — Other — — Total deferred tax liabilities ( 486 ) ( 699 ) Less valuation allowance ( 26,767 ) ( 20,505 ) Net deferred tax assets $ — $ —
Schedule of Unrecognized Tax Benefits	As of December 31, 2022, the Company had the following unrecognized tax benefits (in thousands): Year Ended December 31, 2022 2021 Unrecognized tax benefit beginning balance $ 17 $ 17 Increases for tax positions taken in prior years — — Decreases for tax positions taken in prior years ( 1 ) — Increases for tax positions taken in current years — — Settlements — — Unrecognized tax benefit ending balance $ 16 $ 17

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Summary of Revenues Based on Location of Customers	Revenues based on the location of the customers, are as follows (in thousands): Year Ended December 31, 2022 2021 United States $ 8,836 $ 6,003 Argentina 862 26 India 7 7 Canada 194 503 Spain — 225 United Kingdom — 16 Germany 57 — Total $ 9,956 $ 6,780

Net Loss per Share (Tables)

Net Loss per Share (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Schedule of Securities Not Included in Diluted per Share Calculations	Securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows (in shares): Year Ended December 31, 2022 2021 Options to purchase common stock 60,002 35,554 Warrants to purchase common stock 285,757 287,750 Preferred investment options 123,967 — Total 469,726 323,304

Description of Business - Addit

Description of Business - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Place of incorporation	Arizona
Year of incorporation	2002
Place of reincorporation	Delaware
Date of reincorporation	2015-03
Accumulated deficit	$ (257,859,000)	$ (226,485,000)
Cash and cash equivalents	20,644,000	28,685,000
Net loss	(15,612,000)	(16,134,000)
Net cash used in operations	(13,977,000)	(25,868,000)
Loss on sale of Arcadia Spain		497,000
Impairment charges	$ 160,000	$ 1,400,000
Reverse stock split	In February 2023, the Company’s board of directors approved a reverse split of 40:1 on the Company’s issued and outstanding common stock.

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Line Items]
Net loss attributable to noncontrolling interest	$ 236,000	$ 1,474,000
Loss on disposal of foreign subsidiary		(497,000)
Reserved for doubtful accounts	3,000	76,000
Impairment of intangible assets	404,000	3,302,000
Impairment of goodwill	0	1,648,000
Limagrain Cereal Seeds LLC [Member]
Accounting Policies [Line Items]
Impairment of equity method investments	$ 0	$ 0

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Average Estimated Useful Lives of Assets (Detail)	12 Months Ended
	Dec. 31, 2022
Laboratory equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	5 years
Software and computer equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	3 years
Machinery and equipment [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	2 years
Machinery and equipment [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	20 years
Furniture and fixtures [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	7 years
Vehicles [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	5 years
Leasehold improvements [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	2 years
Leasehold improvements [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	10 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Customers Representing Greater than 10% of Account Receivable and Total Revenue (Details) - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Accounts Receivable [Member] | Customer A
Concentration Risk [Line Items]
Concentration risk percentage	57%
Accounts Receivable [Member] | Customer B
Concentration Risk [Line Items]
Concentration risk percentage		11%
Accounts Receivable [Member] | Customer D
Concentration Risk [Line Items]
Concentration risk percentage		15%
Accounts Receivable [Member] | Customer E
Concentration Risk [Line Items]
Concentration risk percentage		11%
Total Revenue [Member] | Customer B
Concentration Risk [Line Items]
Concentration risk percentage		10%
Total Revenue [Member] | Customer D
Concentration Risk [Line Items]
Concentration risk percentage		11%
Total Revenue [Member] | Customer F
Concentration Risk [Line Items]
Concentration risk percentage	13%

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Amounts Recognized in Consolidated Statements of Operations and Comprehensive Loss Net (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation	$ 1,106	$ 1,541
Research and Development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation	75	98
Selling, General and Administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation	$ 1,031	$ 1,443

Recent Accounting Pronounceme_2

Recent Accounting Pronouncements - Additional Information (Detail) - USD ($) $ in Thousands	Jan. 01, 2022	Jan. 01, 2023	Dec. 31, 2022	Dec. 31, 2021
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Accumulated deficit			$ (257,859)	$ (226,485)
Additional paid-in capital			$ 278,827	$ 257,515
Accounting Standards Update 2016-13 [Member] | Subsequent Event [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]		true
Change in accounting principle, accounting standards update, adoption date		Jan. 01, 2023
Change in accounting principle, accounting standards update, immaterial effect [true false]		true
Accounting Standards Update 2020-06 [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true
Change in accounting principle, accounting standards update, adoption date	Jan. 01, 2022
Accumulated deficit	$ 16,000
Additional paid-in capital	19,400
Decrease in common stock warrant liabilities	$ 3,400
Accounting Standards Update 2021-04 [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true
Change in accounting principle, accounting standards update, adoption date	Jan. 01, 2022
Change in accounting principle, accounting standards update, immaterial effect [true false]	true

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Inventory [Line Items]
Write-down of inventories	$ 2,471,000	$ 3,593,000
Radiance Beauty Licensing Agreement [Member]
Inventory [Line Items]
Write-down of inventories	$ 394,000

Inventory - Summary of Inventor

Inventory - Summary of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 610	$ 1,851
Goods in process	0	842
Finished goods	2,728	4,234
Inventories	$ 3,338	$ 6,927

Property and Equipment, Net - S

Property and Equipment, Net - Summary of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 3,515	$ 7,950
Less accumulated depreciation and amortization	(2,811)	(5,659)
Property and equipment, net	704	2,291
Laboratory equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	679	2,659
Software and computer equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	407	548
Machinery and equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	450	1,809
Furniture and fixtures [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	83	211
Vehicles [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	306	417
Leasehold improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 1,590	$ 2,306

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Depreciation expense	$ 439,000	$ 929,000
Property and equipment, gross	3,515,000	7,950,000
Gain on sale of property and equipment	314,000
Proceeds from sale of property and equipment	920,000	19,000
Assets held for sale		0
Property and equipment classified as assets held for sale, fair value	87,000
Impairments of property and equipment	530,000
Write-down of intangible assets	160,000	1,400,000
Unwinding of Archipelago [Member]
Property Plant And Equipment [Line Items]
Impairments of property and equipment		1,500,000
Radiance Beauty Licensing Agreement [Member]
Property Plant And Equipment [Line Items]
Impairments of property and equipment	320,000
Construction in Progress [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 10,000	$ 267,000

Investments and Fair Value In_3

Investments and Fair Value Instruments - Summary of Amortized Cost and Fair Value of Investment Securities Portfolio (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 18,620	$ 26,842
Unrealized Gains	0	0
Unrealized Losses	0	0
Estimated Fair Value	18,620	26,842
Cash Equivalents [Member] | Money Market Funds [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	18,620	26,842
Unrealized Gains	0	0
Unrealized Losses	0	0
Estimated Fair Value	$ 18,620	$ 26,842

Investments and Fair Value In_4

Investments and Fair Value Instruments - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Investment in continuous unrealized loss position for more than twelve months	$ 0
Realized gain on sale of investments		$ 10,200,000
Impairment charges	$ 404,000	$ 3,302,000

Investments and Fair Value In_5

Investments and Fair Value Instruments - Summary of Fair Value of Investments Securities (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Assets at Fair Value
Total Assets at Fair Value	$ 18,620	$ 26,842
Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	18,620	26,842
Level 1 [Member]
Assets at Fair Value
Total Assets at Fair Value	18,620	26,842
Level 1 [Member] | Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	18,620	26,842
Level 2 [Member]
Assets at Fair Value
Total Assets at Fair Value	0	0
Level 2 [Member] | Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	0	0
Level 3 [Member]
Assets at Fair Value
Total Assets at Fair Value	0	0
Level 3 [Member] | Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	$ 0	$ 0

Investments and Fair Value In_6

Investments and Fair Value Instruments - Summary of Preferred Investment Option Liabilities Measured and Recorded on Recurring Basis using Black-Scholes Model (Detail) - Level 3 [Member]	Dec. 31, 2022
Expected Term [Member] | August 2022 Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Remaining term (in years)	4 years 8 months 1 day
Expected Term [Member] | August 2022 Placement Agent Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Remaining term (in years)	4 years 8 months 1 day
Expected Volatility [Member] | August 2022 Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	106.2
Expected Volatility [Member] | August 2022 Placement Agent Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	106.2
Risk-Free Interest Rate [Member] | August 2022 Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	4
Risk-Free Interest Rate [Member] | August 2022 Placement Agent Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	4
Expected Dividend Yield [Member] | August 2022 Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	0
Expected Dividend Yield [Member] | August 2022 Placement Agent Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	0

Investments and Fair Value In_7

Investments and Fair Value Instruments - Summary of Changes in Fair Value and Other Adjustments of Liabilities (Detail) - Level 3 [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	$ 5,463
Initial recognition	4,015
Change in fair value and other adjustments	(3,279)
Ending Balance	2,806
Reclassification upon Adoption [Member] | ASU 2020-06 [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Ending Balance	(3,393)
Common Stock Warrant Liability [Member] | March 2018 Purchase Agreement [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	7
Initial recognition	0
Change in fair value and other adjustments	0
Ending Balance	0
Common Stock Warrant Liability [Member] | March 2018 Purchase Agreement [Member] | Reclassification upon Adoption [Member] | ASU 2020-06 [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Ending Balance	(7)
Common Stock Warrant Liability [Member] | June 2019 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	170
Initial recognition	0
Change in fair value and other adjustments	0
Ending Balance	0
Common Stock Warrant Liability [Member] | June 2019 Offering [Member] | Reclassification upon Adoption [Member] | ASU 2020-06 [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Ending Balance	(170)
Common Stock Warrant Liability [Member] | September 2019 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	223
Initial recognition	0
Change in fair value and other adjustments	0
Ending Balance	0
Common Stock Warrant Liability [Member] | September 2019 Offering [Member] | Reclassification upon Adoption [Member] | ASU 2020-06 [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Ending Balance	(223)
Common Stock Warrant Liability [Member] | January 2021 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	2,993
Initial recognition	0
Change in fair value and other adjustments	0
Ending Balance	0
Common Stock Warrant Liability [Member] | January 2021 Offering [Member] | Reclassification upon Adoption [Member] | ASU 2020-06 [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Ending Balance	(2,993)
Contingent Liabilities [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	2,070
Initial recognition	0
Change in fair value and other adjustments	(70)
Ending Balance	2,000
Contingent Liabilities [Member] | Reclassification upon Adoption [Member] | ASU 2020-06 [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Ending Balance	0
August 2022 Options [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	0
Initial recognition	3,824
Change in fair value and other adjustments	(3,057)
Ending Balance	767
August 2022 Options [Member] | Reclassification upon Adoption [Member] | ASU 2020-06 [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Ending Balance	0
August 2022 Placement Agent Options [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	0
Initial recognition	191
Change in fair value and other adjustments	(152)
Ending Balance	39
August 2022 Placement Agent Options [Member] | Reclassification upon Adoption [Member] | ASU 2020-06 [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Ending Balance	$ 0

Arcadia Wellness Acquisition -

Arcadia Wellness Acquisition - Additional Information (Detail) - USD ($)			7 Months Ended	12 Months Ended
	May 31, 2021	May 17, 2021	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Total revenues				$ 9,956,000	$ 6,780,000
Net loss attributable to common stockholders				(15,376,000)	(14,660,000)
Inventories written down				2,471,000	3,593,000
Impairments of property and equipment				530,000
Impairment of intangible assets				404,000	3,302,000
Radiance Beauty Licensing Agreement [Member]
Business Acquisition [Line Items]
Accrued salaries				355,000
Accrued rent, maintenance and utilities				$ 19,000
Effective rate of royalty of gross sales				4%
Accounts receivable written-down				$ 21,000
Inventories written down				394,000
Impairments of property and equipment				320,000
Impairment of intangible assets				72,000
Arcadia Wellness [Member]
Business Acquisition [Line Items]
Purchase price consideration	$ 6,100,000
Cash paid for Acquisition	4,000,000
Business combination, equity interest issuable, value	$ 2,100,000
Operating leases, term of contract		3 years
Total revenues			$ 4,300,000	6,500,000
Net loss attributable to common stockholders			$ (7,500,000)	$ (2,100,000)
Intangible assets, net		$ 3,500,000
Weighted average useful life		12 years 10 months 24 days
Goodwill		$ 1,240,000
Arcadia Wellness [Member] | Trademarks and Trade Names [Member]
Business Acquisition [Line Items]
Intangible assets, net		2,900,000
Arcadia Wellness [Member] | Customer List [Member]
Business Acquisition [Line Items]
Intangible assets, net		$ 360,000
Useful life		15 years
Arcadia Wellness [Member] | Formulations [Member]
Business Acquisition [Line Items]
Intangible assets, net		$ 260,000
Useful life		10 years
Arcadia Wellness [Member] | Selling, General and Administrative Expenses [Member]
Business Acquisition [Line Items]
Acquisition related costs					$ 850,000
Common Stock [Member] | Arcadia Wellness [Member]
Business Acquisition [Line Items]
Business combination, equity interest issuable, shares	20,686

Arcadia Wellness Acquisition _2

Arcadia Wellness Acquisition - Schedule of Allocation Purchase Price of Assets Acquired at Fair Value at Acquisition Date (Detail) - Arcadia Wellness [Member] $ in Thousands	May 17, 2021 USD ($)
Business Acquisition [Line Items]
Inventory	$ 840
Prepaid and other current assets	62
Fixed assets	308
Deposits	82
Customer list	360
Trade names and trademarks	2,900
Formulations	260
Goodwill	1,240
Total consideration allocated	$ 6,052

Arcadia Wellness Acquisition _3

Arcadia Wellness Acquisition - Schedule of Unaudited Pro-forma Condensed Consolidated Results of Operations (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Weighted average shares - Basic	599,389	532,016
Weighted average shares - Diluted	599,389	532,016
Arcadia Wellness [Member]
Business Acquisition [Line Items]
Total revenues	$ 9,956	$ 9,062
Net loss	(15,605)	(17,854)
Net loss attributable to common stockholders	$ (15,376)	$ (16,380)
Weighted average shares - Basic	599,389	539,773
Weighted average shares - Diluted	599,389	539,773
Net loss per share attributable to common stockholders:
Basic and diluted	$ (25.65)	$ (30.35)

Intangible Assets, Net - Schedu

Intangible Assets, Net - Schedule of Intangible Assets, Net (Detail) - USD ($) $ in Thousands		Dec. 31, 2022	Dec. 31, 2021
Finite And Indefinite Lived Intangible Assets [Line Items]
Amortized intangible assets, Gross Carrying Amount	[1]	$ 177	$ 970
Amortized intangible assets, Accumulated Amortization		172	774
Finite-Lived Intangible Assets, Net, Total		5	196
Indefinite-lived intangible assets, Gross Carrying Amount	[1]	212	3,920
Indefinite-lived intangible assets, Accumulated Amortization		172	3,436
Indefinite lived intangible assets, Net Carrying Amount		40	484
Brands and Trademarks [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets, Gross Carrying Amount	[1]	35	2,950
Indefinite-lived intangible assets, Accumulated Amortization			2,662
Indefinite lived intangible assets, Net Carrying Amount		35	288
Intellectual Property [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Amortized intangible assets, Gross Carrying Amount	[1]	144	570
Amortized intangible assets, Accumulated Amortization		141	419
Finite-Lived Intangible Assets, Net, Total		3	151
Customer Lists [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Amortized intangible assets, Gross Carrying Amount	[1]	33	400
Amortized intangible assets, Accumulated Amortization		31	355
Finite-Lived Intangible Assets, Net, Total		$ 2	$ 45
[1] During the years ended December 31, 2022 and 2021, the Company estimated an overall decrease in the sales forecast for AW products, due to an inventory item rationalization, in addition to a decrease in the sales forecast of ISI seeds, related to the saturated hemp seed market. As a result, Arcadia performed a quantitative intangible assets impairment test. The Company used a discounted cash flow approach to develop the fair value of our acquired intellectual property, customer lists, brands and trademarks. As a result of this assessment, Arcadia recorded an impairment of intangible assets in the amount of $ 404,000 and $ 3.3 million in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2022 and 2021, respectively. Of the impairment recognized during the year ended December 31, 2022, $ 72,000 was related to the Radiance Beauty licensing agreement.

Intangible Assets, Net - Sche_2

Intangible Assets, Net - Schedule of Intangible Assets, Net (Parenthetical) (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets	$ 404,000	$ 3,302,000
Radiance Beauty Licensing Agreement [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets	$ 72,000

Consolidated Joint Venture - Ad

Consolidated Joint Venture - Additional Information (Detail)		12 Months Ended
	Aug. 09, 2019 Individual	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Schedule Of Equity Method Investments [Line Items]
Net loss attributable to noncontrolling interest		$ 236,000	$ 1,474,000
Archipelago Ventures Hawaii, LLC [Member] | Arcadia Biosciences, Inc [Member]
Schedule Of Equity Method Investments [Line Items]
Number of individuals appointed | Individual	2
Joint venture interest percentage		50.75%
Capital contributions		$ 3,100,000
Archipelago Ventures Hawaii, LLC [Member] | Legacy Ventures Hawaii, LLC [Member]
Schedule Of Equity Method Investments [Line Items]
Number of individuals appointed | Individual	2
Joint venture interest percentage		49.25%
Capital contributions		$ 3,000,000

Verdeca-BIOX Transactions - Add

Verdeca-BIOX Transactions - Additional Information (Detail) - USD ($)		1 Months Ended	3 Months Ended	12 Months Ended
	Nov. 12, 2020	Jun. 30, 2021	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Variable Interest Entity [Line Items]
Fixed consideration allocated to sale of membership interest				$ 569,000
Gain on sale of membership interests in Verdeca				1,138,000	0
Inventory contributed				2,571,000	4,433,000
Revenues				9,956,000	6,780,000
Gross proceeds on sale		$ 22,200,000
Proceeds from sale of Verdeca in accounts receivable and other receivables				569,000	0
Remaining accounts receivable and other receivables				1,287,000	1,370,000
License
Variable Interest Entity [Line Items]
Revenues				879,000	$ 17,000
Bioceres Crop Solutions [Member] | License
Variable Interest Entity [Line Items]
Revenues			$ 862,000
Verdeca LLC [Member]
Variable Interest Entity [Line Items]
Gain on sale of membership interests in Verdeca			$ 1,100,000
Verdeca LLC [Member] | Bioceres Crop Solutions [Member]
Variable Interest Entity [Line Items]
Milestone Payments Received				1,000,000
Verdeca LLC [Member] | Bioceres Crop Solutions [Member] | Accounts Receivables and Other Receivables [Member]
Variable Interest Entity [Line Items]
Milestone payment receivable from sale of interest in joint venture				$ 1,000,000
Verdeca LLC [Member] | Bioceres Crop Solutions [Member] | Master Transaction Agreement [Member]
Variable Interest Entity [Line Items]
Cash receivable from sale of interest in joint venture	$ 5,000,000
Shares of common stock receivable from sale of interest in joint venture	1,875,000
Additional cash receivable for transaction expenses and fees	$ 1,000,000
Milestone payment receivable from sale of interest in joint venture	$ 2,000,000
Sale of interest in joint venture, description of transaction				BIOX also paid the Company an additional $1,000,000 for transaction expenses and fees and is obligated to pay $2,000,000 in four equal quarterly payments with the first payment commencing within thirty days of either BIOX reaching commercial plantings of at least 200,000 hectares of HB4 soybeans or China approving the HB4 soybean trait for “food and feed”.
Percentage of royalty payments on net revenues	6%
Percentage of royalty payments on net revenues received from sales of licensed wheat products	25%
Sale of interest in joint venture, fixed consideration agreed amount	$ 16,968,750
Fixed consideration allocated to sale of membership interest	10,288,000
Corporate securities received allocated to sale of member ship interest	6,650,000
Gain on sale of membership interests in Verdeca						$ 8,814,000
Inventory contributed						1,474,000
Verdeca LLC [Member] | Bioceres Crop Solutions [Member] | Master Transaction Agreement [Member] | License
Variable Interest Entity [Line Items]
Revenues						6,680,000
Corporate securities						$ 4,318,000
Verdeca LLC [Member] | Bioceres Crop Solutions [Member] | Master Transaction Agreement [Member] | Maximum [Member]
Variable Interest Entity [Line Items]
Technology royalty revenue receivable on trait fees, from sale of interest in joint venture	$ 10,000,000

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accounts payable - trade	$ 931	$ 1,411
Payroll and benefits	1,373	1,606
Inventory	69	72
Royalty fees due to unrelated parties	6	51
Consulting	8	79
Rent and utilities	28	127
Audit and tax fees	99	72
Legal	69	58
Other	298	162
Total accounts payable and accrued expenses	$ 2,881	$ 3,638

Collaborative Arrangements - Ad

Collaborative Arrangements - Additional Information (Detail)	1 Months Ended
	Aug. 31, 2017
Collaborative Arrangements [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contractual agreement month and year	2017-08

Equity Financing - Additional I

Equity Financing - Additional Information (Detail)		1 Months Ended							12 Months Ended
	Aug. 16, 2022 USD ($) $ / shares	Aug. 31, 2022 USD ($) $ / shares shares	Jan. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Sep. 30, 2019 USD ($) $ / shares shares	Jun. 30, 2019 USD ($) $ / shares shares	Jun. 30, 2018 USD ($) $ / shares shares	Mar. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2022 USD ($)	Jun. 30, 2022 $ / shares	Jan. 28, 2021
Class Of Warrant Or Right [Line Items]
Stock price | $ / shares										$ 40
Maximum [Member]
Class Of Warrant Or Right [Line Items]
Proceeds from issuance, aggregate offering prices | $									$ 50,000,000
March 2018 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued								30,041
Warrant issued, shares of common stock called by warrant								32,071
Warrants issued, exercise price | $ / shares								$ 429.03
August 2022 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued		61,250
Offering closing period		Aug. 16, 2022
August 2022 Purchase Agreement [Member] | Pre Funded Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant		56,813
Warrants issued, exercise price | $ / shares		$ 0.004
August 2022 Purchase Agreement [Member] | Preferred Investment Options [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued		118,063
Exercise price | $ / shares		$ 37.35
Proceeds from issuance of common stock, pre-funded warrants and preferred investment options | $		$ 5,000,000
Warrants expiration period		5 years
December 2020 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued				65,467
Proceeds from issuance of common stock and warrants gross | $				$ 8,000,000
Offering closing period				Dec. 22, 2020
December 2020 Purchase Agreement [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant				65,467
Warrants issued, exercise price | $ / shares				$ 120
Warrants expiration period				5 years 6 months
September 2019 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued					32,971
Proceeds from issuance of common stock and warrants gross | $					$ 10,000,000
Offering closing period					Sep. 05, 2019
September 2019 Purchase Agreement [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant					16,486
Warrants issued, exercise price | $ / shares					$ 300.80
Warrants expiration period					5 years 6 months
June 2019 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued						37,240
Proceeds from issuance of common stock and warrants gross | $						$ 7,500,000
Offering closing period						Jun. 14, 2019
June 2019 Purchase Agreement [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant						37,240
Warrants issued, exercise price | $ / shares						$ 200
Warrants expiration period						5 years 6 months
June 2018 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued							34,809
Proceeds from issuance of common stock and warrants gross | $							$ 14,000,000
Offering closing period							Jun. 14, 2018
June 2018 Purchase Agreement [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant							34,809
Warrants issued, exercise price | $ / shares							$ 397.60
Warrants expiration period							5 years 6 months
June 2018 Placement Agent Warrants [Member] | June 2018 Purchase Agreement [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant							1,741
Warrants issued, exercise price | $ / shares							$ 502.72
Warrant, exercisable term							5 years
June 2019 Placement Agent Warrants [Member] | June 2019 Purchase Agreement [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant						1,862
Warrants issued, exercise price | $ / shares						$ 251.75
Warrant, exercisable term						5 years
September 2019 Placement Agent Warrants [Member] | September 2019 Purchase Agreement [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant					1,649
Warrants issued, exercise price | $ / shares					$ 379.12
Warrant, exercisable term					5 years
August 2022 Options and August 2022 Placement Agent Options [Member]
Class Of Warrant Or Right [Line Items]
Expected volatility	128.46%
Stock price | $ / shares	$ 37.60
Risk-free interest rate	2.97%
Expected term	5 years
August 2022 Placement Agent Options [Member]
Class Of Warrant Or Right [Line Items]
Fair value assumptions, value | $	$ 191,000
Offering costs | $	488,000
Allocation of common stock option liability expense | $	314,000
Remaining offering costs allocated to common stock and offset to additional paid in capital | $	365,000
August 2022 Placement Agent Options [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Offering costs | $	$ 679,000
August 2022 Placement Agent Options [Member] | August 2022 Purchase Agreement [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant		5,904
Warrants issued, exercise price | $ / shares		$ 52.80
Warrant, exercisable term		5 years
December 2020 Placement Agent Warrants [Member] | December 2020 Purchase Agreement [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant				3,274
Warrants issued, exercise price | $ / shares				$ 152.75
Warrant, exercisable term				5 years
January 2021 Private Placement [Member] | January 2021 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued			196,920
Warrant issued, shares of common stock called by warrant			98,460
Warrants issued, exercise price | $ / shares			$ 125.20
Proceeds from issuance of common stock and warrants gross | $			$ 25,100,000
Warrants expiration period			5 years 6 months
Remaining offering costs allocated to common stock and offset to additional paid in capital | $			$ 2,000,000
January 2021 Private Placement [Member] | January 2021 Purchase Agreement [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Offering costs allocated to common stock warrant liability and expensed | $			$ 769,000
January 2021 Private Placement [Member] | January 2021 Purchase Agreement [Member] | Warrants [Member] | Expected Volatility [Member]
Class Of Warrant Or Right [Line Items]
Preferred investment options liability, measurement input											1.238
January 2021 Private Placement [Member] | January 2021 Purchase Agreement [Member] | Warrants [Member] | Stock Price [Member]
Class Of Warrant Or Right [Line Items]
Preferred investment options liability, measurement input											1.1520
January 2021 Private Placement [Member] | January 2021 Purchase Agreement [Member] | Warrants [Member] | Risk-Free Interest Rate [Member]
Class Of Warrant Or Right [Line Items]
Preferred investment options liability, measurement input											0.05
January 2021 Private Placement [Member] | January 2021 Placement Agent Warrants [Member] | January 2021 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant			9,846
Warrants issued, exercise price | $ / shares			$ 159.60
Offering costs | $			$ 1,900,000
Warrant, exercisable term			5 years 6 months
Issuance of placement agent warrants | $			$ 942,000
January 2021 Private Placement [Member] | January 2021 Placement Agent Warrants [Member] | January 2021 Purchase Agreement [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Offering costs | $			$ 2,800,000
March 2018 Private Placement [Member] | March 2018 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued								7,519
Warrant issued, shares of common stock called by warrant								7,519
Warrants issued, exercise price | $ / shares								$ 1,830
Proceeds from issuance of common stock and warrants gross | $								$ 10,000,000
Warrants expiration period								5 years
March 2018 Private Placement [Member] | March 2018 Placement Agent Warrants [Member] | March 2018 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant								376
Warrants issued, exercise price | $ / shares								$ 1,662.50
Warrant, exercisable term								5 years

Warrants and Options - Summary

Warrants and Options - Summary of Warrants Issued to Purchase Common Stock (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Class Of Warrant Or Right [Line Items]
Warrants Exercised during the Year	0	0
Warrants Outstanding	342,570	287,757
December 2022 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2022-12
Term	5 years
Exercise Price Per Share	$ 11.20
Warrants Exercised during the Year	0	0
Warrants Outstanding	1,000	0
October 2022 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2022-10
Term	5 years
Exercise Price Per Share	$ 16
Warrants Exercised during the Year	0	0
Warrants Outstanding	1,000	0
August 2022 Pre-Funded Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2022-08
Term	perpetual
Exercise Price Per Share	$ 0
Warrants Exercised during the Year	0	0
Warrants Outstanding	56,813	0
January 2021 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2021-01
Term	5 years 6 months
Exercise Price Per Share	$ 159.60
Warrants Exercised during the Year	0	0
Warrants Outstanding	9,846	9,846
January 2021 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2021-01
Term	2 years
Exercise Price Per Share	$ 123.20
Warrants Exercised during the Year	0	0
Warrants Outstanding	188	188
December 2020 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-12
Term	5 years 6 months
Exercise Price Per Share	$ 120
Warrants Exercised during the Year	0	0
Warrants Outstanding	65,467	65,467
December 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-12
Term	5 years
Exercise Price Per Share	$ 152.80
Warrants Exercised during the Year	0	0
Warrants Outstanding	3,274	3,274
July 2020 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-07
Term	5 years 6 months
Exercise Price Per Share	$ 154
Warrants Exercised during the Year	0	0
Warrants Outstanding	16,036	16,036
July 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-07
Term	5 years 6 months
Exercise Price Per Share	$ 198.80
Warrants Exercised during the Year	0	0
Warrants Outstanding	802	802
May 2020 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-05
Term	5 years
Exercise Price Per Share	$ 191.20
Warrants Exercised during the Year	0	0
Warrants Outstanding	34,809	34,809
May 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-05
Term	5 years
Exercise Price Per Share	$ 245.20
Warrants Exercised during the Year	0	0
Warrants Outstanding	1,741	1,741
March 2020 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-03
Term	3 years
Exercise Price Per Share	$ 100
Warrants Exercised during the Year	0	0
Warrants Outstanding	459	459
February 12, 2020 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-02
Term	2 years
Exercise Price Per Share	$ 188.40
Warrants Exercised during the Year	0	0
Warrants Outstanding	0	3,750
February 3, 2020 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-02
Term	2 years
Exercise Price Per Share	$ 196.40
Warrants Exercised during the Year	0	0
Warrants Outstanding	0	250
September 2019 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-09
Term	5 years
Exercise Price Per Share	$ 379.20
Warrants Exercised during the Year	0	0
Warrants Outstanding	1,649	1,649
June 2019 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-06
Term	5 years
Exercise Price Per Share	$ 251.60
Warrants Exercised during the Year	0	0
Warrants Outstanding	1,862	1,862
April 2019 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-04
Term	5 years
Exercise Price Per Share	$ 247.20
Warrants Exercised during the Year	0	0
Warrants Outstanding	3,629	3,629
June 2018 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2018-06
Term	5 years
Exercise Price Per Share	$ 502.80
Warrants Exercised during the Year	0	0
Warrants Outstanding	1,741	1,741
March 2018 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2018-03
Term	5 years
Exercise Price Per Share	$ 1,662.40
Warrants Exercised during the Year	0	0
Warrants Outstanding	376	376
January 2021 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2021-01
Term	5 years 6 months
Exercise Price Per Share	$ 125.20
Warrants Exercised during the Year	0	0
Warrants Outstanding	98,460	98,460
September 2019 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-09
Term	5 years 6 months
Exercise Price Per Share	$ 300.80
Warrants Exercised during the Year	0	0
Warrants Outstanding	16,486	16,486
June 2019 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-06
Term	5 years 6 months
Exercise Price Per Share	$ 200
Warrants Exercised during the Year	0	0
Warrants Outstanding	10,896	10,896
June 2018 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2018-06
Term	5 years 6 months
Exercise Price Per Share	$ 397.60
Warrants Exercised during the Year	0	0
Warrants Outstanding	0	0
March 2018 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2018-03
Term	5 years
Exercise Price Per Share	$ 429.20
Warrants Exercised during the Year	0	0
Warrants Outstanding	16,036	16,036

Warrants and Options - Summar_2

Warrants and Options - Summary of Warrants Issued to Purchase Common Stock (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2022
February 12, 2020 Service and Performance Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant expiration month and year	2022-02
February 3, 2020 Service and Performance Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant expiration month and year	2022-02

Warrants and Options - Summar_3

Warrants and Options - Summary of Key Terms and Activity of Liability Classified Preferred Investment Options (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
August 2022 Options [Member]
Option Indexed to Issuer's Equity [Line Items]
Issuance Date	2022-08
Term	5 years
Exercise Price Per Share	$ 37.20
Exercised during the year	0	0
Outstanding	118,063	0
August 2022 Placement Agent Options [Member]
Option Indexed to Issuer's Equity [Line Items]
Issuance Date	2022-08
Term	5 years
Exercise Price Per Share	$ 52.80
Exercised during the year	0	0
Outstanding	5,904	0
August 2022 Options and Placement Agent Options [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercised during the year	0	0
Outstanding	123,967	0

Stock-Based Compensation and _3

Stock-Based Compensation and Employee Stock Purchase Program - Additional Information (Detail)							1 Months Ended	12 Months Ended
	Feb. 02, 2022 shares	Dec. 19, 2021	Dec. 14, 2021	May 17, 2021 shares	May 20, 2015 shares	May 14, 2015	Jun. 30, 2019 shares	Dec. 31, 2022 USD ($) IncentivePlan $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity incentive plans | IncentivePlan								2
Shares Subject to Outstanding, Options granted								33,408	30,676
Total number of options outstanding								60,002	35,554	22,243
Intrinsic value of options exercisable | $								$ 0	$ 0
Unrecognized compensation cost related to unvested stock-based compensation grants | $								$ 1,100,000
Weighted-average remaining recognition period								2 years 4 months 24 days
Stock-based compensation | $								$ 1,106,000	$ 1,541,000
Weighted-average estimated grant-date fair value of stock options granted | $ / shares								$ 38.50	$ 96.40
2015 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares reserved for issuance under plan								3,122
Stock-based compensation | $								$ 4,000	$ 14,000
Percentage in payroll deductions to acquire shares of common stock						15%
Purchase plan offering period						6 months
Employees are able to purchase company's common stock on first trading day of offering period, percentage						85%
Issuance of common stock pursuant to employee stock purchase plan								1,475
First offering period, start date						May 14, 2015
First offering period, end date						Feb. 01, 2016
Separation Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercisable period		2 years 6 months	90 days
Separation Agreement [Member] | Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation | $									$ 154,000
Inducement Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Subject to Outstanding, Options granted				6,200
Total number of options outstanding								8,477
Inducement Stock Option [Member] | Stanley Jacot, Jr. [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Subject to Outstanding, Options granted	7,902
2015 Omnibus Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Terms under the plan								The 2015 Plan became effective upon the Company’s IPO in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 3,860 shares of common stock reserved for future issuance, which included 259 that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan.
Total number of shares reserved for issuance under plan					3,860			62,192
Options vesting period					4 years
Additional shares authorized for issuance under the plan							3,000
Common stock available for future grant								10,771
Total number of options outstanding								51,421	33,648
2006 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares reserved for issuance under plan					259
Total number of options outstanding								103	206
Maximum [Member] | 2015 Omnibus Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercisable period					10 years

Stock-Based Compensation and _4

Stock-Based Compensation and Employee Stock Purchase Program - Summary of Activity Under Stock Incentive Plans (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]
Shares Subject to Outstanding, Beginning Balance	35,554	22,243
Shares Subject to Outstanding, Options granted	33,408	30,676
Shares Subject to Outstanding, Options exercised	0	0
Shares Subject to Outstanding, Options Forfeited	(6,658)	(11,004)
Shares Subject to Outstanding, Options Expired	(2,302)	(6,361)
Shares Subject to Outstanding, Ending Balance	60,002	35,554
Shares Subject to Outstanding, Vested and expected to vest	54,018
Shares Subject to Outstanding, Exercisable	22,456
Weighted-Average Exercise Price Per Share, Outstanding Beginning Balance	$ 211.20	$ 578.40
Weighted-Average Exercise Price Per Share, Options granted	44	110.40
Weighted-Average Exercise Price Per Share, Options exercised	0	0
Weighted-Average Exercise Price Per Share, Options forfeited	91.60	123.60
Weighted-Average Exercise Price Per Share, Options expired	644.80	1,160.80
Weighted Average Exercise Price Per Share, Outstanding Ending Balance	114.80	$ 211.20
Weighted Average Exercise Price Per Share, Vested and expected to vest	121.60
Weighted Average Exercise Price Per Share, Exercisable	$ 215.20
Aggregate Intrinsic Value, Beginning Balance	$ 0	$ 9,600,000
Aggregate Intrinsic Value, Options Granted	11,880,000	0
Aggregate Intrinsic Value, Options Exercised	0	0
Aggregate Intrinsic Value, Options Forfeited	0	43,440,000
Aggregate Intrinsic Value, Options Expired	0	0
Aggregate Intrinsic Value, Ending Balance	0	$ 0
Aggregate Intrinsic Value, Vested and expected to vest	0
Aggregate Intrinsic Value, Exercisable	$ 0

Stock-Based Compensation and _5

Stock-Based Compensation and Employee Stock Purchase Program - Weighted-Average Fair Value Assumption of Stock Option Awards (Detail) - Employee Stock Option [Member]	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	6 years 4 months 24 days	6 years 3 months 21 days
Expected volatility	122%	121%
Risk-free interest rate	2.61%	0.86%
Expected dividend yield	0%	0%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	1 Months Ended	12 Months Ended
	Aug. 31, 2020 USD ($) Installment shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2010 USD ($) Program	Jun. 15, 2005 USD ($)
Commitments And Contingencies [Line Items]
Other noncurrent liability		$ 2,000,000	$ 2,070,000
Change in fair value of contingent consideration		(70,000)	(210,000)
Milestones payments achieved		2,000,000
Accounts Payable and Accrued Expenses [Member]
Commitments And Contingencies [Line Items]
Royalties due to both related and unrelated parties on accrued		$ 54,000	115,000
Anawah, Inc [Member]
Commitments And Contingencies [Line Items]
Contingent liability				$ 3,000,000	$ 5,000,000
Date of merger and reorganization		Jun. 15, 2005
Restructuring activities, description		As of December 31, 2010, the Company ceased activities relating to three of the six Anawah product programs
Number of development programs ceased | Program				3
Number of development programs | Program				6
Other noncurrent liability		$ 2,000,000
Industrial Seed Innovations [Member]
Commitments And Contingencies [Line Items]
Remaining amount paid in multiple installments	$ 280,000
Change in fair value of contingent consideration		$ (70,000)	$ (210,000)
Industrial Seed Innovations [Member] | Common Stock [Member]
Commitments And Contingencies [Line Items]
Number of annual installment of common stock shares payable | Installment	2
Minimum [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract		1 year
Royalty payments due, percentage of net revenue as defined in the In-Licensing agreements		2%
Maximum [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract		5 years
Royalty payments due, percentage of net revenue as defined in the In-Licensing agreements		15%
Maximum [Member] | Industrial Seed Innovations [Member] | Common Stock [Member] | Revenue Milestone in 2022 [Member]
Commitments And Contingencies [Line Items]
Business combination, equity interest issuable upon achievement of revenue milestone | shares	3,316

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Lessee Lease Description [Line Items]
Sublease, description of option to extend	lease amendment that provided for additional office space in Davis, CA, and extended the term through April 2025, with one option to renew for an additional five-year term. The Company initially expected to exercise its options to renew, and in accordance with ASC 842, Leases, accounted for the amendment and expected renewal as a lease modification and remeasured the operating lease liability.
Operating Lease, Liability	$ 2,017,000	$ 3,294,000
Right of use assets	$ 1,848,000	3,081,000
Existence of option to extend	true
Lease option to extend, description	Some leases (the Davis and Dallas offices, a warehouse, and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years
Operating lease term, expiration	2024-05
Early termination fees	$ 47,000
Minimum [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term	1 year
Operating leases, term of contract	1 year
Maximum [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term	6 years
Operating leases, term of contract	5 years
ASU 2016-02
Lessee Lease Description [Line Items]
Operating Lease, Liability		2,800,000
Right of use assets		$ 2,600,000
Office Space [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term		5 years	5 years

Leases - Schedule of Leases (De

Leases - Schedule of Leases (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Assets
Operating lease assets	$ 1,848	$ 3,081
Total leased assets	1,848	3,081
Liabilities
Current - Operating	1,010	1,074
Noncurrent - Operating	1,007	2,220
Total leased liabilities	2,017	3,294
Lease Cost
Net lease cost	$ 650	$ 1,422
Lease Term and Discount Rate
Weighted-average remaining lease term (years)	2 years 4 months 24 days	2 years 8 months 12 days
Weighted-average discount rate	6%	6%
SG&A and R&D Expenses [Member]
Lease Cost
Operating lease cost	$ 1,028	$ 1,352
Short term lease cost	6	133
Sublease income	$ (384)	$ (63)

Leases - Schedule of Maturities

Leases - Schedule of Maturities of Operating Lease Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Lessee Disclosure [Abstract]
2023	$ 1,104
2024	886
2025	156
2026 and thereafter	0
Total operating lease payments	2,146
Less: imputed interest	129
Operating Lease, Liability	$ 2,017	$ 3,294

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)	Feb. 26, 2021	Jun. 26, 2020	May 18, 2020	Dec. 31, 2021	Apr. 16, 2020
Promissory Note [Member] | Paycheck Protection Program [Member]
Debt Instrument [Line Items]
Debt instrument, face amount					$ 1,100,000
Promissory Notes [Member[ | MidFirst Bank [Member]
Debt Instrument [Line Items]
Interest rate			2.50%
Debt instrument maturity date			May 18, 2023
Debt instrument outstanding amount				$ 0
Line of credit facility initiation date		Jun. 26, 2020
Line of credit facility maximum borrowing capacity		$ 2,000,000
Line of credit facility agreement date			May 18, 2020
Debt instrument interest rate terms			Pursuant to the Loan Agreement, the Note accrued interest, adjusted monthly, at a rate equal to the greater of (i) 3.25% and (ii) the sum of (a) the quotient of the LIBOR Index divided by (one minus the reserve requirement set by the Federal Reserve), and (b) 2.50%.
Repayments of line of credit	$ 2,000,000
Minimum [Member] | Promissory Notes [Member[ | MidFirst Bank [Member]
Debt Instrument [Line Items]
Interest rate			3.25%
Maximum [Member] | Promissory Notes [Member[ | MidFirst Bank [Member]
Debt Instrument [Line Items]
Line of credit facility maximum borrowing capacity			$ 2,000,000

Income Taxes - Components of Lo

Income Taxes - Components of Loss Before Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Domestic	$ (15,598)	$ (16,006)
Foreign	0	(126)
Loss before income taxes	$ (15,598)	$ (16,132)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Income Tax [Line Items]
Income tax expense	$ 14,000	$ 2,000
Increase (decrease) in net valuation allowance	$ 6,300,000	$ (6,000,000)
Operating loss carryforwards limitations on use	it has not forfeited the right to carryforward tax losses up to 20 years
Tax years subject to examination to extent of NOLs being carried forward	2003
Maximum [Member]
Schedule Of Income Tax [Line Items]
Right to carryforward tax losses, period	20 years
Tax year subject to examination by the tax authorities	2022
Minimum [Member]
Schedule Of Income Tax [Line Items]
Tax year subject to examination by the tax authorities	2003
Federal [Member]
Schedule Of Income Tax [Line Items]
Aggregate amount of net operating loss	$ 81,100,000
Operating loss carryforward	222,300,000
Operating loss carryforward expected to be unavailable	141,200,000
State [Member]
Schedule Of Income Tax [Line Items]
Aggregate amount of net operating loss	$ 47,500,000

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Tax Expense Comprised of Current State Taxes and Foreign Taxes (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Current:
Federal	$ 0	$ 0
State	(13,000)	(2,000)
Foreign	(1,000)	0
Total current tax (expense)	(14,000)	(2,000)
Deferred:
Federal	0	0
State	0	0
Foreign	0	0
Total deferred tax (expense)	0	0
Total tax (expense)	$ (14,000)	$ (2,000)

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Statutory Federal Income Tax Rate to the Company's Effective Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Expected income tax provision at the federal statutory rate	21%	21%
State taxes, net of federal benefits	16%	(20.10%)
Impact of Section 382 Study	0%	(10.40%)
Change in valuation allowance	(40.90%)	(0.40%)
Transaction costs	0%	(1.00%)
Derivative liability	4.10%	11.70%
Contingent Consideration Release	0.10%	0%
Non-controlling Interest	(0.30%)	(1.90%)
Gain on debt extinguishment	0%	1.50%
Other	(0.10%)	(0.40%)
Income tax provision	(0.10%)	0%

Income Taxes - Summary of Compa

Income Taxes - Summary of Company's Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:
Net operating loss carryforwards	$ 19,654	$ 14,586
Unearned revenue	0	1
Stock-based compensation	4,541	3,677
Accrued payroll and benefits	296	3
Research and development credits	16	16
Fixed asset basis difference	54	73
Inventory reserve	445	422
Charitable contributions	2	2
Income from partnerships	97	163
Lease liability	531	752
Contingent consideration	0	456
Allowance for bad debt	65	27
Amortized intangibles	819	660
Goodwill	393	366
Section 174 Capitalization	340	0
Total deferred tax assets	27,253	21,204
Deferred tax liabilities:
Right of use asset	(486)	(699)
Amortizable intangibles	0	0
Income from Partnerships	0	0
Other	0	0
Total deferred tax liabilities	(486)	(699)
Less valuation allowance	(26,767)	(20,505)
Net deferred tax assets	$ 0	$ 0

Income Taxes - Schedule of Unre

Income Taxes - Schedule of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Unrecognized tax benefit beginning balance	$ 17	$ 17
Increases for tax positions taken in prior years	0	0
Decreases for tax positions taken in prior years	(1)	0
Increases for tax positions taken in current years	0	0
Settlements	0	0
Unrecognized tax benefit ending balance	$ 16	$ 17

Retirement Benefits - Additiona

Retirement Benefits - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Retirement Benefits [Abstract]
Employer matching contribution, percent	50%
Maximum annual contribution per employee, percent	3%
Description of defined contribution pension and other postretirement plans	Employees’ rights to employer contributions vest on the one-year anniversary of their date of employment.
Defined benefit plan employee vested minimum period, years	1 year
Amount accrued for company's approved discretionary match	$ 0	$ 0

Segment and Geographic Informat

Segment and Geographic Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2022 Segment
Segment Reporting [Abstract]
Number of operating segment	1

Segment and Geographic Inform_2

Segment and Geographic Information - Summary of Revenues Based on Location of Customers (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	$ 9,956	$ 6,780
United States
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	8,836	6,003
Argentina
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	862	26
India
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	7	7
Canada
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	194	503
Spain
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues		225
United Kingdom
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues		$ 16
Germany
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	$ 57

Net Loss per Share - Summary of

Net Loss per Share - Summary of Securities Not Included in Diluted Per Share Calculations (Detail) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	469,726	323,304
Option to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	60,002	35,554
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	285,757	287,750
Preferred Investment Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	123,967	0

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail)	1 Months Ended				12 Months Ended
	Feb. 01, 2022 USD ($)	Apr. 30, 2020 USD ($) a Lease	Mar. 31, 2020 USD ($) a	Feb. 28, 2019 USD ($) a	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Related Party Transaction [Line Items]
Royalty fees due					$ 48,000	$ 64,000
Number of lease amendments | Lease		2
Lease payments					0	84,000
Mr. Kevin Comcowich [Member]
Related Party Transaction [Line Items]
Acres of land | a				10
Operating leases, term of contract				2 years
Rent payments				$ 1,200
Mr. Kevin Comcowich [Member] | Amendment [Member]
Related Party Transaction [Line Items]
Acres of land | a		15	10
Operating leases, term of contract		2 years	2 years
Number of additional properties under lease agreement		two additional 15-acre parcels	two additional 10-acre parcels
Rent payments		$ 1,200	$ 1,200
Mr. Comcowich [Member]
Related Party Transaction [Line Items]
Total compensation for service	$ 34,000
John Sperling Foundation [Member]
Related Party Transaction [Line Items]
Royalty fees due					$ 48,000	$ 64,000

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Securities Purchase Agreement [Member] - USD ($) $ / shares in Units, $ in Millions	Mar. 06, 2023	Mar. 02, 2022
March 2023 Pre Funded Warrants [Member]
Subsequent Event [Line Items]
Warrant issued, shares of common stock called by warrant		500,834
Warrants issued, exercise price		$ 0.0001
Preferred Investment Options [Member]
Subsequent Event [Line Items]
Warrant issued, shares of common stock called by warrant		1,332,668
Warrants issued, exercise price		$ 9
Proceeds from issuance of common stock and warrants gross		$ 6
Preferred Investment Options [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Warrants exercisable	666,334
Warrants expiration period	18 months
Remaining warrants exercisable	666,334
Remaining warrants expiration period	5 years
March 2023 PIPE Shares [Member]
Subsequent Event [Line Items]
Shares of common stock issued		165,500
March 2023 PIPE Shares [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Warrant issued, shares of common stock called by warrant	178,132
Offering closing period	Mar. 06, 2023
March 2023 PIPE Shares [Member] | March 2023 Placement Agent Options [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Warrant issued, shares of common stock called by warrant	33,317
Warrants issued, exercise price	$ 11.25
Warrant, exercisable term	5 years